ISPY_ID	DATAEXTRACTDT	INST_ID	AGECAT	RACE_ID	SSTAT	SURVDTD	CHEMO	TAM	HERCEPTIN	MENOSTATUS	SENTINELNODESAMPLE	SENTINELNODERESULT	HISTOLOGICGRADEOS	ER_TS	PGR_TS	HER2COMMUNITYPOS	HER2COMMUNITYMETHOD	SURGERYLUMPECTOMY	SURGERYMASTECTOMY	INITLUMP_FUPMAST	SURGERY	DCISONLY	PTUMOR1SZCM_MICRO	HISTOLOGICGRADEPS	NUMPOSNODES	NODESEXAMINED	PATHOLOGYSTAGE	RTTHERAPY	RTBREAST	RTBOOST	RTAXILLA	RTSNODE	RTIMAMNODE	RTCHESTW	RTOTHER	TSIZECLINICAL	NSIZECLINICAL	STAGETE	STAGENE	STAGEME	CLINICALSTAGE	CLINRESPT1_T2	CLINRESPT1_T3	CLINRESPT1_T4	CHEMOCAT	DOSEDENSEANTHRA	DOSEDENSETAXANE	LES_T1	LES_T2	LES_T3	LES_T4	LD_T1	LD_T2	LD_T3	LD_T4	LD_T1_T2_PERCT	LD_T1_T3_PERCT	LD_T1_T4_PERCT	LD_T2_T3_PERCT	LD_T2_T4_PERCT	LD_T3_T4_PERCT	MRI_PATTERN_CODE	MRI_PATTERN_DESC	CDNA_T1	CDNA_T2	CDNA_T3	CDNA_T4	AGI_T1	AGI_T2	AGI_T3	AGI_T4	IHC_T1	IHC_T2	IHC_T3	IHC_T4	FISH_T1	FISH_T2	FISH_T3	FISH_T4
1001	04/16/2007	508=U Ca at San Francisco	2= >30-40	White	8=Dead	1270	6=AC->Td		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		4=Indeterminate	7 = Positive	2 = Negative	0=negative	2=FISH	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both				2	9	1=Stage 0 (DCIS only)	2=Yes	0=No	0=No	0=No	1=Yes	0=No	0=No	0=No	4	3	2	2	0	5=Stage IIIA	3=Stable Disease	2=PR	1=CR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks	0= Standard Therapy, q3 wks	Regonal	Regonal	Regonal	Regonal	88	78	30	14	-11.36	-65.91	-84.09	-61.54	-82.05	-53.33	4	Area enhancement with irregular margins (WITHOUT modularity)	209515	209521			209515	209521			209512	209518			209512			
1002	04/16/2007	508=U Ca at San Francisco	2= >30-40	White	8=Dead	1156	6=AC->Td		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		2=Grade II (intermediate)	8 = Positive	8 = Positive	0=negative	2=FISH	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both		2	3=Grade III (high)	3		3=Stage IIA	2=Yes	0=No	0=No	0=No	0=No	0=No	0=No	1=Yes	4	1	2	1	0	4=Stage IIB	3=Stable Disease	3=Stable Disease	3=Stable Disease	2=Anthracycline Plus Taxane		0= Standard Therapy, q3 wks	Mass	Mass	Mass	Mass	29	26	66	16	-10.34	127.59	-44.83	153.85	-38.46	-75.76	2	Multi-lobulated mass with well-defined margins	209534			215147	209534			215147	209532	209545		215144				215144
1003	04/16/2007	508=U Ca at San Francisco	3= >40-50	White	7=Alive	1541	6=AC->Td		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No			8 = Positive	8 = Positive	0=negative	2=FISH	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		4	2=Grade II (intermediate)	2	13	4=Indeterminate	2=Yes	0=No	0=No	0=No	1=Yes	0=No	1=Yes	0=No	9	2.5	3	1	0	5=Stage IIIA	3=Stable Disease		3=Stable Disease	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks	0= Standard Therapy, q3 wks	Mass	Mass	Mass	Mass	50	64	54	46	28	8	-8	-15.63	-28.13	-14.81	2	Multi-lobulated mass with well-defined margins				215151				215151	209555			215148				215148
1004	04/16/2007	939=U Penn	3= >40-50	White	7=Alive	1539	6=AC->Td		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		4=Indeterminate	0 = Negative	0 = Negative	0=negative	2=FISH	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		1.5	3=Grade III (high)	3	15	7=Stage IIIC	2=Yes	0=No	0=No	0=No	1=Yes	0=No	0=No	1=Yes	5.7	2	3	1	0	5=Stage IIIA	4=Progressive Disease	4=Progressive Disease	2=PR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	91	90	99	43	-1.1	8.79	-52.75	10	-52.22	-56.57	3	Area enhancement with irregular margins (WITH modularity)	229389	209500		210761	209389	209500			209386	209498		210760	209386	209498		210760
1005	04/16/2007	939=U Penn	3= >40-50	White	7=Alive	1652	6=AC->Td		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	1=Yes	1=Positive	2=Grade II (intermediate)			0=negative	1=IHC	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both		2.7	2=Grade II (intermediate)	3	15	4=Indeterminate	2=Yes	0=No	0=No	1=Yes	1=Yes	0=No	0=No	0=No	9		3	1	0	5=Stage IIIA	3=Stable Disease	2=PR	2=PR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks	0= Standard Therapy, q3 wks	Mass	Mass	Mass	Mass	98	109	60	42	11.22	-38.78	-57.14	-44.95	-61.47	-30	5	Septal spread; streaming	209633			212394	209633			212394	209631	209681		212392	209631	209681		212392
1007	04/16/2007	372=U North Carolina at Chapel Hill	3= >40-50	White	7=Alive	1399	1=AC			1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	1=Yes	0=Negative	3=Grade III (high)	8 = Positive	8 = Positive	0=negative	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		2.5	2=Grade II (intermediate)		4	3=Stage IIA									4.5							3=Stable Disease	3=Stable Disease	1=Anthracycline Only Regimen	0= Standard Therapy, q3 wks		Mass	Mass		Mass	100	100		54	0		-46		-46		1	Single uni-centric mass with well-defined margin	210239								210237	210248			210237	210248		
1008	04/16/2007	508=U Ca at San Francisco	5= >60-70	White	7=Alive	1264	6=AC->Td		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No		2=Grade II (intermediate)	8 = Positive	8 = Positive	0=negative	1=IHC	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both		1.8	4=Indeterminate	0	8	2=Stage I	2=Yes	1=Yes	1=Yes	0=No	0=No	0=No	0=No	1=Yes	5.5	0.8	2	1	0	4=Stage IIB	2=PR	2=PR	2=PR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	45	49	47	32	8.89	4.44	-28.89	-4.08	-34.69	-31.91	2	Multi-lobulated mass with well-defined margins	210311			215155					210308	210364		215152	210308			215152
1009	04/16/2007	508=U Ca at San Francisco	3= >40-50	Asian	7=Alive	1464	6=AC->Td		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		3=Grade III (high)	0 = Negative	0 = Negative	0=negative	2=FISH	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both		1.3	3=Grade III (high)	0	16	2=Stage I	2=Yes	1=Yes	0=No	1=Yes	0=No	0=No	0=No	0=No	7	1.5	3	0	0	4=Stage IIB	2=PR	1=CR	1=CR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks	0= Standard Therapy, q3 wks	Mass	Mass	Mass	Mass	75	66	57	7	-12	-24	-90.67	-13.64	-89.39	-87.72	2	Multi-lobulated mass with well-defined margins	210832	210841		215163	210832	210841			210830	210838		215160	210830	210838		215160
1010	04/16/2007	508=U Ca at San Francisco	3= >40-50	White	7=Alive	1358	7=AC->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		3=Grade III (high)	0 = Negative	0 = Negative	0=negative	1=IHC	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both				0	23	1=Stage 0 (DCIS only)	2=Yes	1=Yes	0=No	0=No	1=Yes	0=No	0=No	0=No			3	0	0	4=Stage IIB	2=PR	2=PR	1=CR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks	0= Standard Therapy, q3 wks	Mass	Mass	Mass	Mass	60	52	20	3	-13.33	-66.67	-95	-61.54	-94.23	-85	1	Single uni-centric mass with well-defined margin	211773								211767	211776			211767	211776		
1011	04/16/2007	508=U Ca at San Francisco	3= >40-50	Asian	7=Alive	1371	7=AC->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		4=Indeterminate	0 = Negative	0 = Negative	0=negative	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both				0	10	1=Stage 0 (DCIS only)	2=Yes	1=Yes	0=No	0=No	1=Yes	0=No	0=No	0=No	6.5	4	2	1	0	4=Stage IIB	2=PR	1=CR	1=CR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	68	68	56	47	0	-17.65	-30.88	-17.65	-30.88	-16.07	2	Multi-lobulated mass with well-defined margins	211754				211754				211748				211748			
1012	04/16/2007	508=U Ca at San Francisco	4= >50-60	Black or African American	7=Alive	1204	6=AC->Td		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		2=Grade II (intermediate)	8 = Positive	7 = Positive	0=negative	1=IHC	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both				0	18	4=Indeterminate	2=Yes	1=Yes	1=Yes	0=No	0=No	0=No	0=No	1=Yes	9	2	4	1	0	6=Stage IIIB	2=PR	2=PR	2=PR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks	0= Standard Therapy, q3 wks	Regonal	Regonal	Regonal	Regonal	78	84	56	57	7.69	-28.21	-26.92	-33.33	-32.14	1.79	3	Area enhancement with irregular margins (WITH modularity)	211738	211746			211739	211746			211733	211740		215170	211733	211740		215170
1013	04/16/2007	508=U Ca at San Francisco	3= >40-50	White	7=Alive	1501	6=AC->Td		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		1=Grade I (low)			0=negative	1=IHC	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both		7.1	1=Grade I (low)	7	17	5=Stage IIIA	2=Yes	0=No	0=No	1=Yes	1=Yes	0=No	1=Yes	0=No	7	2	3	1	0	5=Stage IIIA	3=Stable Disease	2=PR	1=CR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks	0= Standard Therapy, q3 wks	Regonal	Regonal	Regonal	Regonal	71	70	8	5	-1.41	-88.73	-92.96	-88.57	-92.86	-37.5	4	Area enhancement with irregular margins (WITHOUT modularity)	211720								211714	211723		215174	211714	211723		215174
1015	04/16/2007	508=U Ca at San Francisco	3= >40-50	White	7=Alive	1452	6=AC->Td		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		3=Grade III (high)	6 = Positive	0 = Negative	1=positive(Any 3+ or FISH ratio >= 2)	2=FISH	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both				0	14	1=Stage 0 (DCIS only)									3	1					3=Stable Disease	2=PR	1=CR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks		Regonal	Regonal	Regonal	Regonal	79	50	11	3	-36.71	-86.08	-96.2	-78	-94	-72.73	5	Septal spread; streaming										211706				211706		
1016	04/16/2007	939=U Penn	2= >30-40	White	7=Alive	1425	6=AC->Td		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		2=Grade II (intermediate)	6 = Positive	6 = Positive	0=negative	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		1.5		0	6	2=Stage I	2=Yes	0=No	0=No	1=Yes	1=Yes	0=No	0=No	0=No	5.1	1.5	3	1	0	5=Stage IIIA	3=Stable Disease	2=PR	1=CR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks	0= Standard Therapy, q3 wks	Mass	Mass	Mass	Regonal	73	60	57	36	-17.81	-21.92	-50.68	-5	-40	-36.84	2	Multi-lobulated mass with well-defined margins	210891	210965		215302	210891	210965			210889	210961		215299	210889	210961		
1017	04/16/2007	508=U Ca at San Francisco	5= >60-70	White	8=Dead	918	16=AC-> TpTd 		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No		4=Indeterminate	0 = Negative	0 = Negative			1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both		2.3	3=Grade III (high)	3	11	3=Stage IIA	2=Yes	1=Yes	1=Yes	0=No	1=Yes	0=No	0=No	1=Yes	6	2	3	1	0	5=Stage IIIA	3=Stable Disease	3=Stable Disease	2=PR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks		Mass		Mass	Mass	54		27	16		-50	-70.37			-40.74	1	Single uni-centric mass with well-defined margin	211648	211657							211647			234953	211647			
1018	04/16/2007	372=U North Carolina at Chapel Hill	4= >50-60	White	7=Alive	1354	7=AC->Tp		0=No	5=Indeterminate, not 1 or 2 above	1=Yes	0=Negative	2=Grade II (intermediate)	8 = Positive	8 = Positive	0=negative	1=IHC	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both		0.7	2=Grade II (intermediate)		1	2=Stage I	2=Yes	0=No	0=No	0=No	0=No	0=No	0=No	0=No	4						4=Progressive Disease	3=Stable Disease	3=Stable Disease	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	50	37	33	26	-26	-34	-48	-10.81	-29.73	-21.21	3	Area enhancement with irregular margins (WITH modularity)	212061								212059				212059	212093		
1019	04/16/2007	939=U Penn	4= >50-60	Black or African American	7=Alive	1482	6=AC->Td		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No		3=Grade III (high)	0 = Negative	0 = Negative	0=negative	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		7.5	3=Grade III (high)	0	15	4=Indeterminate	2=Yes	0=No	0=No	0=No	0=No	0=No	0=No	0=No	12.5		4	0	0	6=Stage IIIB	2=PR	2=PR	4=Progressive Disease	2=Anthracycline Plus Taxane		0= Standard Therapy, q3 wks	Mass	Mass	Mass	Mass	115	68	33	67	-40.87	-71.3	-41.74	-51.47	-1.47	103.03	1	Single uni-centric mass with well-defined margin	211158			215402	211158	211230			211155	211227		215399	211155	211227		215399
1021	04/16/2007	508=U Ca at San Francisco	3= >40-50	White	7=Alive	910	6=AC->Td		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No		3=Grade III (high)	6 = Positive	3 = Positive	1=positive(Any 3+ or FISH ratio >= 2)	2=FISH	1=yes	0=no	1=Yes	2= Delayed surgery (>8 weeks); other than primary RT				0	4	1=Stage 0 (DCIS only)									7	1	4	2	0	6=Stage IIIB	4=Progressive Disease	1=CR	1=CR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks		Regonal	Regonal			63	55	0	0	-12.7	-100	-100	-100	-100	0	3	Area enhancement with irregular margins (WITH modularity)	211643				211643				211641			230783	211641			
1022	04/16/2007	2647=U Alabama (Birmingham)	4= >50-60	White	7=Alive	1230	7=AC->Tp		0=No	5=Indeterminate, not 1 or 2 above	0=No		4=Indeterminate	8 = Positive	0 = Negative	0=negative	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		0		14	18	3=Stage IIA									6	1.5	3	1	0	5=Stage IIIA	3=Stable Disease	2=PR	1=CR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks	0= Standard Therapy, q3 wks		Regonal	Regonal	Regonal	98	91	76	75	-7.14	-22.45	-23.47	-16.48	-17.58	-1.32	5	Septal spread; streaming	214441	214453			214441	214453			214435	214447		216760	214435	214447		216760
1024	04/16/2007	372=U North Carolina at Chapel Hill	4= >50-60	White	7=Alive	1435	7=AC->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	1=Yes	1=Positive	3=Grade III (high)	7 = Positive	0 = Negative	0=negative	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both				8	22	5=Stage IIIA	2=Yes	0=No	0=No	0=No	1=Yes	0=No	1=Yes	0=No	7	1.5	3	1	0	5=Stage IIIA	3=Stable Disease	3=Stable Disease	3=Stable Disease	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks	1= Dose Dense Therapy, q2 wks	Mass				76	76		0	0		-100		-100		3	Area enhancement with irregular margins (WITH modularity)	212113				212114				212103	212184			212103	212184		
1025	04/16/2007	508=U Ca at San Francisco	4= >50-60	White	8=Dead	718	16=AC-> TpTd 		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		4=Indeterminate			0=negative	1=IHC				6=No, Other Reason, Not specified															11		3	0	0	4=Stage IIB	3=Stable Disease	2=PR		2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks	0= Standard Therapy, q3 wks	Mass	Mass	Mass	Mass	47	45	42	42	-4.26	-10.64	-10.64	-6.67	-6.67	0	2	Multi-lobulated mass with well-defined margins									211633	211637			211633	211637		
1026	04/16/2007	939=U Penn	3= >40-50	White	7=Alive	1358	6=AC->Td		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		4=Indeterminate			1=positive(Any 3+ or FISH ratio >= 2)	2=FISH	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both				0	12	1=Stage 0 (DCIS only)	2=Yes	0=No	0=No	0=No	0=No	0=No	0=No	0=No	3.5	2	2	1	0	4=Stage IIB	3=Stable Disease	2=PR	2=PR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks	0= Standard Therapy, q3 wks	Mass	Mass	Mass		32	25	14	0	-21.88	-56.25	-100	-44	-100	-100	1	Single uni-centric mass with well-defined margin	211629	211886			211629				211625	211882						
1027	04/16/2007	2647=U Alabama (Birmingham)	2= >30-40	Black or African American	7=Alive	1071	1=AC			1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		4=Indeterminate	2 = Negative	0 = Negative	2=indeterminate(2+)	1=IHC	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both		0	3=Grade III (high)	0	31		2=Yes	0=No	1=Yes	0=No	1=Yes	0=No	1=Yes	0=No	3		2	0	0	3=Stage IIA	3=Stable Disease		4=Progressive Disease	1=Anthracycline Only Regimen	0= Standard Therapy, q3 wks		Mass	Mass	Mass		40	37	65		-7.5	62.5		75.68			1	Single uni-centric mass with well-defined margin	214699	214707			214699				214693	214701			214693	214701		
1028	04/16/2007	372=U North Carolina at Chapel Hill	4= >50-60	White	8=Dead	289	7=AC->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		3=Grade III (high)	0 = Negative	0 = Negative	0=negative	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		0		2	11	6=Stage IIIB									8	3	4	1	X	6=Stage IIIB	3=Stable Disease	1=CR	1=CR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks		Mass	Mass	Mass		60	60	49	0	0	-18.33	-100	-18.33	-100	-100	2	Multi-lobulated mass with well-defined margins	212312	212323			212312				214506	212316			214506			
1029	04/16/2007	508=U Ca at San Francisco	5= >60-70	White	7=Alive	1475	6=AC->Td		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No		2=Grade II (intermediate)	7 = Positive	5 = Positive	1=positive(Any 3+ or FISH ratio >= 2)	1=IHC	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both		1.8	4=Indeterminate	3	30	3=Stage IIA	2=Yes	1=Yes	0=No	0=No	1=Yes	0=No	0=No	1=Yes	3.5	0.8	2	1	0	4=Stage IIB	3=Stable Disease	2=PR	1=CR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks	0= Standard Therapy, q3 wks	Mass	Mass	Mass	Mass	46	50	41	39	8.7	-10.87	-15.22	-18	-22	-4.88	2	Multi-lobulated mass with well-defined margins	212288	212298							212283	212293		219294	212283	212293		219294
1031	04/16/2007	508=U Ca at San Francisco	4= >50-60	White	7=Alive	1418	7=AC->Tp		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No							1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both		3	2=Grade II (intermediate)	3	4	3=Stage IIA	2=Yes	1=Yes	0=No	0=No	1=Yes	0=No	0=No	0=No	0	2	3	1	0	5=Stage IIIA	3=Stable Disease	3=Stable Disease	2=PR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	43	38	36	34	-11.63	-16.28	-20.93	-5.26	-10.53	-5.56	2	Multi-lobulated mass with well-defined margins	212619	212629			212619				212613	212624			212613			
1032	04/16/2007	508=U Ca at San Francisco	2= >30-40	Asian	7=Alive	1387	16=AC-> TpTd 		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		2=Grade II (intermediate)	8 = Positive	8 = Positive	0=negative	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		1.6	2=Grade II (intermediate)	2	9	3=Stage IIA	2=Yes	1=Yes	0=No	0=No	1=Yes	0=No	0=No	0=No	9		2	1	0	4=Stage IIB	3=Stable Disease	3=Stable Disease	2=PR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks		Regonal	Regonal	Regonal	Regonal	60	50	47	52	-16.67	-21.67	-13.33	-6	4	10.64	3	Area enhancement with irregular margins (WITH modularity)	212695	212837		219335	212695				212689	212833			212689	212833	215229	
1033	04/16/2007	372=U North Carolina at Chapel Hill	4= >50-60	White	7=Alive	1383	7=AC->Tp		0=No	5=Indeterminate, not 1 or 2 above	1=Yes	1=Positive	2=Grade II (intermediate)	8 = Positive	5 = Positive	0=negative	2=FISH	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both				0	23	4=Indeterminate	2=Yes	0=No	1=Yes	0=No	1=Yes	0=No	1=Yes	0=No	8		3	0		4=Stage IIB	3=Stable Disease	3=Stable Disease	2=PR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	130	64	64	69	-50.77	-50.77	-46.92	0	7.81	7.81	4	Area enhancement with irregular margins (WITHOUT modularity)	212914	212924							212908	212918		217536	212908	212918		
1034	04/16/2007	939=U Penn	3= >40-50	White	8=Dead	555	7=AC->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		4=Indeterminate	0 = Negative	0 = Negative	0=negative	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		0.2		8	10	5=Stage IIIA	2=Yes	0=No	0=No	0=No	1=Yes	0=No	1=Yes	0=No	8	1.5	3	3	0	7=Stage IIIC	2=PR	2=PR	1=CR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Regonal		88	82	0	0	-6.82	-100	-100	-100	-100	0	4	Area enhancement with irregular margins (WITHOUT modularity)	213088	213158		218662	213088	213158			213082	213152		218661	213082	213152		
1035	04/16/2007	530=Mem Sloan-Kettering Cancer Ctr	3= >40-50	White	7=Alive	1177	7=AC->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		2=Grade II (intermediate)	5 = Positive	4 = Positive	1=positive(Any 3+ or FISH ratio >= 2)	2=FISH				6=No, Other Reason, Not specified															17		4	3	0	7=Stage IIIC	3=Stable Disease	3=Stable Disease	2=PR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Regonal	100	90	60	41	-10	-40	-59	-33.33	-54.44	-31.67	4	Area enhancement with irregular margins (WITHOUT modularity)	213782	214064			213782	214064			213777	214058			213777	214058		
1036	04/16/2007	508=U Ca at San Francisco	2= >30-40	White	7=Alive	1024	3=FEC		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		2=Grade II (intermediate)	0 = Negative	0 = Negative	1=positive(Any 3+ or FISH ratio >= 2)	1=IHC	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both		0.6	2=Grade II (intermediate)	0	12	2=Stage I	2=Yes	1=Yes	0=No	0=No	1=Yes	0=No	0=No	1=Yes	11	1.5					3=Stable Disease		1=CR	1=Anthracycline Only Regimen	0= Standard Therapy, q3 wks		Regonal	Regonal		Regonal	101	100		83	-0.99		-17.82		-17		5	Septal spread; streaming		215253							215236	215247			215236	215247		
1037	04/16/2007	2647=U Alabama (Birmingham)	4= >50-60	White	7=Alive	1147	7=AC->Tp		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No		4=Indeterminate	0 = Negative	0 = Negative	0=negative	2=FISH	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both				0	17	2=Stage I									6	1.5	3	1	0	5=Stage IIIA	3=Stable Disease	2=PR	1=CR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass		92	84	82	82	-8.7	-10.87	-10.87	-2.38	-2.38	0	1	Single uni-centric mass with well-defined margin		214493			214474	214493			214468	214487			214468	214487		
1038	04/16/2007	2647=U Alabama (Birmingham)	2= >30-40	Black or African American	7=Alive	1187	7=AC->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		4=Indeterminate	0 = Negative	0 = Negative	0=negative	1=IHC	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both				1	31	3=Stage IIA	2=Yes	1=Yes	1=Yes	0=No	1=Yes	0=No	0=No	0=No	7		3	1	0	5=Stage IIIA	3=Stable Disease			2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks		Mass	Mass	Mass		36	26	36	22	-27.78	0	-38.89	38.46	-15.38	-38.89	1	Single uni-centric mass with well-defined margin	214462	214485			214462	214485			214456	214479			214456	214479		
1039	04/16/2007	372=U North Carolina at Chapel Hill	2= >30-40	Black or African American	7=Alive	1226	7=AC->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	1=Yes	0=Negative	3=Grade III (high)	0 = Negative	0 = Negative	1=positive(Any 3+ or FISH ratio >= 2)	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both					2	4=Indeterminate									3		2	0	0	3=Stage IIA	3=Stable Disease	2=PR	1=CR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	20	20	17	12	0	-15	-40	-15	-40	-29.41	4	Area enhancement with irregular margins (WITHOUT modularity)		214987		219184		214987				214982				214982		
1040	04/16/2007	540=Georgetown	4= >50-60	White	8=Dead	462	7=AC->Tp		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No		2=Grade II (intermediate)	0 = Negative	0 = Negative	0=negative	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		3.5	3=Grade III (high)	5	5	5=Stage IIIA	2=Yes	0=No	0=No	1=Yes	0=No	1=Yes	1=Yes	1=Yes	8	3	3	2	0	5=Stage IIIA	3=Stable Disease	3=Stable Disease	2=PR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks	0= Standard Therapy, q3 wks	Mass	Mass		Mass	69	64		50	-7.25		-27.54		-21.88		3	Area enhancement with irregular margins (WITH modularity)				222543					215499	216084		222542	215499	216084		
1041	04/16/2007	508=U Ca at San Francisco	3= >40-50	White	9=Lost	701	6=AC->Td		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		3=Grade III (high)			1=positive(Any 3+ or FISH ratio >= 2)	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		5.2	2=Grade II (intermediate)	22	28	6=Stage IIIB	2=Yes	1=Yes	0=No	0=No	1=Yes	0=No	0=No	0=No	9	2	3	3	0	7=Stage IIIC	3=Stable Disease		2=PR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks	0= Standard Therapy, q3 wks	Mass	Mass	Mass	Mass	90	86	86	53	-4.44	-4.44	-41.11	0	-38.37	-38.37	2	Multi-lobulated mass with well-defined margins	217144	217155		221273	217144	217155			217138	217149		221270	217138	217149		221270
1042	04/16/2007	939=U Penn	4= >50-60	White	7=Alive	1249	6=AC->Td		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No	0=Negative	4=Indeterminate	7 = Positive	3 = Positive	0=negative	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		0.2		0	8	2=Stage I	2=Yes	0=No	0=No	0=No	0=No	0=No	1=Yes	0=No	3		2	0	0	3=Stage IIA	4=Progressive Disease	2=PR	2=PR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks	0= Standard Therapy, q3 wks	Mass	Mass	Mass	Regonal	93	19	76	40	-79.57	-18.28	-56.99	300	110.53	-47.37	3	Area enhancement with irregular margins (WITH modularity)	215309	215397			215309	215397			215303	215391			215303	215391		
1043	04/16/2007	939=U Penn	2= >30-40	White	8=Dead	746	6=AC->Td		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		4=Indeterminate	0 = Negative	4 = Positive	2=indeterminate(2+)	4=Unknown	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		0.8	2=Grade II (intermediate)	3	9	3=Stage IIA									13		4	1	0	6=Stage IIIB	3=Stable Disease	1=CR	1=CR	2=Anthracycline Plus Taxane		0= Standard Therapy, q3 wks	Mass	Mass	Regonal	Mass	138	146	141	39	5.8	2.17	-71.74	-3.42	-73.29	-72.34	4	Area enhancement with irregular margins (WITHOUT modularity)	215630	215655			215630	215655			215624	215649			215624	215649		
1044	04/16/2007	2647=U Alabama (Birmingham)	4= >50-60	Black or African American	8=Dead	456	1=AC		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No		4=Indeterminate	0 = Negative	0 = Negative	0=negative	1=IHC	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both		0	3=Grade III (high)	14	28	5=Stage IIIA	2=Yes	0=No	1=Yes	1=Yes	1=Yes	0=No	1=Yes		14	4					3=Stable Disease		3=Stable Disease	1=Anthracycline Only Regimen	0= Standard Therapy, q3 wks		Mass			Mass	154			129			-16.23				3	Area enhancement with irregular margins (WITH modularity)	216826	217000		219035	216826				216820	216995		219032	216820	216995		219032
1045	04/16/2007	530=Mem Sloan-Kettering Cancer Ctr	3= >40-50	Black or African American	8=Dead	538	7=AC->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		3=Grade III (high)					1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both				0	11		2=Yes	1=Yes	1=Yes	0=No	0=No	0=No	0=No	0=No	14	1.5	3		0		3=Stable Disease	2=PR	2=PR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Regonal	Regonal	120	42	96	30	-65	-20	-75	128.57	-28.57	-68.75	4	Area enhancement with irregular margins (WITHOUT modularity)	216719	216803			216719	216803			216709	216797						
1046	04/16/2007	372=U North Carolina at Chapel Hill	3= >40-50	White	7=Alive	1044	1=AC			1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	1=Yes	0=Negative	1=Grade I (low)	6 = Positive	8 = Positive	0=negative	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both			1=Grade I (low)		2	3=Stage IIA									4		2	0	0	3=Stage IIA	3=Stable Disease		3=Stable Disease	1=Anthracycline Only Regimen	0= Standard Therapy, q3 wks		Mass	Mass		Mass	44	27		27	-38.64		-38.64		0		4	Area enhancement with irregular margins (WITHOUT modularity)	217567				217568				217562	217573			217562	217573		
1047	04/16/2007	939=U Penn	1=  18-30	White	7=Alive	1211	1=AC	1=Yes	0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	1=Yes	1=Positive				0=negative	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		0.2		0	25	3=Stage IIA	2=Yes	0=No	0=No	1=Yes	1=Yes	0=No	1=Yes	0=No	7		3	0	0	4=Stage IIB	3=Stable Disease	2=PR	2=PR	1=Anthracycline Only Regimen	0= Standard Therapy, q3 wks	0= Standard Therapy, q3 wks	Mass	Mass	Mass	Mass	73	80	70	25	9.59	-4.11	-65.75	-12.5	-68.75	-64.29	3	Area enhancement with irregular margins (WITH modularity)	218395								218391							
1048	04/16/2007	530=Mem Sloan-Kettering Cancer Ctr	4= >50-60	White	7=Alive	1178	7=AC->Tp		0=No	5=Indeterminate, not 1 or 2 above	0=No		1=Grade I (low)	8 = Positive	7 = Positive	0=negative	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		2.3	3=Grade III (high)	13	29	7=Stage IIIC	2=Yes	0=No	0=No	1=Yes	1=Yes	0=No	1=Yes	0=No	7		3				3=Stable Disease	3=Stable Disease	3=Stable Disease	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Regonal	Regonal	Regonal	Regonal	120	91	85	45	-24.17	-29.17	-62.5	-6.59	-50.55	-47.06	4	Area enhancement with irregular margins (WITHOUT modularity)	217909	217917							217901	217911		223358	217901	217911		
1049	04/16/2007	2647=U Alabama (Birmingham)	4= >50-60	White	8=Dead	361	7=AC->Tp		0=No		0=No		4=Indeterminate	0 = Negative	0 = Negative	0=negative	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both			3=Grade III (high)	16	16	8=Stage IV										5	4	1	X	6=Stage IIIB				2=Anthracycline Plus Taxane		1= Dose Dense Therapy, q2 wks	Regonal	Regonal	Regonal	Regonal	127	111	90	81	-12.6	-29.13	-36.22	-18.92	-27.03	-10	3	Area enhancement with irregular margins (WITH modularity)	217408	217594		222752	217408	217594			217402	217588		222748	217402			
1050	04/16/2007	2647=U Alabama (Birmingham)	5= >60-70	White	8=Dead	669	7=AC->Tp		0=No	5=Indeterminate, not 1 or 2 above	0=No		4=Indeterminate	0 = Negative	0 = Negative	0=negative	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		0	3=Grade III (high)	0	27	2=Stage I	2=Yes	1=Yes	1=Yes	0=No	1=Yes	0=No	0=No	0=No	6	2.5	3	1	X	5=Stage IIIA	3=Stable Disease	2=PR	2=PR	2=Anthracycline Plus Taxane		1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	41	34	22	0	-17.07	-46.34	-100	-35.29	-100	-100	1	Single uni-centric mass with well-defined margin	217419				217419				217413	217581			217413	217581		
1051	04/16/2007	508=U Ca at San Francisco	3= >40-50	White	7=Alive	912	7=AC->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		2=Grade II (intermediate)	6 = Positive	7 = Positive	0=negative	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		0		0	2	1=Stage 0 (DCIS only)	2=Yes	0=No	0=No	0=No	0=No	0=No	0=No	0=No	6		2	0	0	3=Stage IIA	3=Stable Disease	2=PR	2=PR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks	0= Standard Therapy, q3 wks			Regonal	Regonal	102		87	79		-14.71	-22.55			-9.2	4	Area enhancement with irregular margins (WITHOUT modularity)	219353	219365								219359						
1053	04/16/2007	372=U North Carolina at Chapel Hill	5= >60-70	White	7=Alive	1258	5=A		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	1=Yes	0=Negative	2=Grade II (intermediate)	8 = Positive	8 = Positive	0=negative	1=IHC	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both			1=Grade I (low)		4	2=Stage I	2=Yes	1=Yes	0=No	0=No	0=No	0=No	0=No	0=No	4.5		3	0	0	4=Stage IIB	2=PR		3=Stable Disease	1=Anthracycline Only Regimen	0= Standard Therapy, q3 wks		Mass	Mass		Mass	27	36		30	33.33		11.11		-16.67		2	Multi-lobulated mass with well-defined margins									229756	218226		221138		218226		
1054	04/16/2007	2647=U Alabama (Birmingham)	3= >40-50	Black or African American	7=Alive	192	7=AC->Tp		0=No	5=Indeterminate, not 1 or 2 above	0=No		4=Indeterminate	0 = Negative	0 = Negative	0=negative	1=IHC	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both		0	3=Grade III (high)	2	8	5=Stage IIIA	2=Yes	0=No	1=Yes	0=No	1=Yes	0=No	1=Yes	0=No	5	2	2	1	X	4=Stage IIB		1=CR	1=CR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Regonal	Regonal	Regonal	Regonal	97	106	103	84	9.28	6.19	-13.4	-2.83	-20.75	-18.45	5	Septal spread; streaming	218012	218048		223312					218006	218042		223308	218006	218042		
1055	04/16/2007	530=Mem Sloan-Kettering Cancer Ctr	4= >50-60	White	7=Alive	1153	7=AC->Tp		0=No	5=Indeterminate, not 1 or 2 above	0=No		2=Grade II (intermediate)	8 = Positive	8 = Positive	0=negative	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		3	1=Grade I (low)	3	27	4=Indeterminate	2=Yes	0=No	0=No	0=No	0=No	0=No	0=No	0=No	9.5		2	0	0	3=Stage IIA	3=Stable Disease	2=PR	2=PR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	50	50	50	37	0	0	-26	0	-26	-26	2	Multi-lobulated mass with well-defined margins	218564			244239	218564				218558	218569		223357	218558	218569		
1056	04/16/2007	508=U Ca at San Francisco	2= >30-40	White	8=Dead	215	6=AC->Td		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		2=Grade II (intermediate)	0 = Negative	0 = Negative	1=positive(Any 3+ or FISH ratio >= 2)	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both				13	18	7=Stage IIIC										3.5	2	3	0	7=Stage IIIC	3=Stable Disease	2=PR	1=CR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks	0= Standard Therapy, q3 wks	Regonal	Regonal	Regonal	Regonal	108	108	105	92	0	-2.78	-14.81	-2.78	-14.81	-12.38	4	Area enhancement with irregular margins (WITHOUT modularity)	219429	219440		227672				227672	219423				219423			
1057	04/16/2007	939=U Penn	3= >40-50	White	8=Dead	313	7=AC->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		2=Grade II (intermediate)	0 = Negative	0 = Negative	0=negative	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		0.1		4	11	5=Stage IIIA										6.5	4	1	0	6=Stage IIIB	3=Stable Disease	3=Stable Disease	2=PR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Regonal	Mass	Regonal		105	101	87	0	-3.81	-17.14	-100	-13.86	-100	-100	5	Septal spread; streaming	218367	218378			218367				218361	218372			218361			
1058	04/16/2007	2647=U Alabama (Birmingham)	4= >50-60	White	7=Alive	1097	7=AC->Tp		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No		3=Grade III (high)	0 = Negative	0 = Negative	0=negative	1=IHC	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both				0	13	1=Stage 0 (DCIS only)	2=Yes	1=Yes	1=Yes	0=No	1=Yes	0=No	0=No	0=No	3		2	0	X	3=Stage IIA	3=Stable Disease	2=PR	1=CR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks		Mass	Mass	Mass	Mass	38	23	6	15	-39.47	-84.21	-60.53	-73.91	-34.78	150	2	Multi-lobulated mass with well-defined margins	218520	218617			218521				218514	218612			218514	218612		
1059	04/16/2007	372=U North Carolina at Chapel Hill	4= >50-60	White	7=Alive	1036	7=AC->Tp		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	1=Yes	0=Negative	1=Grade I (low)	8 = Positive	5 = Positive	0=negative	1=IHC	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both			1=Grade I (low)		16	3=Stage IIA	2=Yes	0=No	0=No	0=No	0=No	0=No	0=No	0=No	3.5						3=Stable Disease	3=Stable Disease		2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass		20	13	17		-35	-15		30.77			3	Area enhancement with irregular margins (WITH modularity)		218988		225613					218971	218982		225610	218971	218982		
1060	04/16/2007	2527=U Texas SW Med Ctr	5= >60-70	Black or African American	7=Alive	925	6=AC->Td		0=No	5=Indeterminate, not 1 or 2 above	0=No		3=Grade III (high)	8 = Positive	5 = Positive	0=negative	3=Other	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		0.1		0	12	2=Stage I	2=Yes	1=Yes	0=No	0=No	1=Yes	0=No	0=No	0=No	7.5	5	3	1	0	5=Stage IIIA	3=Stable Disease	2=PR		2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks	0= Standard Therapy, q3 wks	Mass	Mass	Mass	Mass	72	66	45	30	-8.33	-37.5	-58.33	-31.82	-54.55	-33.33	2	Multi-lobulated mass with well-defined margins	220639								220635	222102			220635	222102		
1061	04/16/2007	508=U Ca at San Francisco	4= >50-60	White	8=Dead	659	6=AC->Td		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No		3=Grade III (high)	2 = Negative	0 = Negative	1=positive(Any 3+ or FISH ratio >= 2)	2=FISH	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both		1.5	3=Grade III (high)	0	37	2=Stage I	2=Yes	1=Yes	1=Yes	0=No	0=No	0=No	0=No	0=No	6.5	1	3	1	0	5=Stage IIIA	2=PR	2=PR	2=PR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks	0= Standard Therapy, q3 wks	Regonal	Regonal	Regonal	Regonal	60	57	18	20	-5	-70	-66.67	-68.42	-64.91	11.11	4	Area enhancement with irregular margins (WITHOUT modularity)	219372			227878				227878	219366	219377		227875	219366	219377		
1062	04/16/2007	508=U Ca at San Francisco	2= >30-40	White	7=Alive	861	19=AC->Td->Xeloda		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		3=Grade III (high)	3 = Positive	3 = Positive	0=negative	1=IHC	0=no	0=no		0=Delayed surgery (>8 weeks); following RT		12.4		4	8	5=Stage IIIA									8.5		3	1	0	5=Stage IIIA	3=Stable Disease	4=Progressive Disease	4=Progressive Disease	4=Anthracycline + Taxane + Other	0= Standard Therapy, q3 wks	1= Dose Dense Therapy, q2 wks	Regonal	Regonal	Regonal	Regonal	77	85	100	98	10.39	29.87	27.27	17.65	15.29	-2	3	Area enhancement with irregular margins (WITH modularity)	219391			227805		219402			219385	219396		227802	219385			
1064	04/16/2007	508=U Ca at San Francisco	5= >60-70	White	7=Alive	882	6=AC->Td		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No		3=Grade III (high)	0 = Negative	0 = Negative	0=negative	1=IHC																			7.5	1	2	1	0	4=Stage IIB	3=Stable Disease	1=CR	1=CR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks		Mass	Mass	Mass	Mass	70	67	47	30	-4.29	-32.86	-57.14	-29.85	-55.22	-36.17	3	Area enhancement with irregular margins (WITH modularity)	219410								219404				219404			
1065	04/16/2007	2527=U Texas SW Med Ctr	4= >50-60	Black or African American	9=Lost	913	6=AC->Td		0=No	5=Indeterminate, not 1 or 2 above	0=No		2=Grade II (intermediate)	8 = Positive	4 = Positive	1=positive(Any 3+ or FISH ratio >= 2)	2=FISH	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both			2=Grade II (intermediate)	3	11	4=Indeterminate	2=Yes	1=Yes	1=Yes	0=No	1=Yes	0=No	0=No	0=No	6	3	4	1	0	6=Stage IIIB	3=Stable Disease	2=PR	2=PR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks	0= Standard Therapy, q3 wks	Mass	Mass	Mass	Mass	55	50	40	25	-9.09	-27.27	-54.55	-20	-50	-37.5	1	Single uni-centric mass with well-defined margin	223060			240957					223043	223123		239288	223043	223123		
1066	04/16/2007	2647=U Alabama (Birmingham)	4= >50-60	White	7=Alive	909	7=AC->Tp		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	1=Yes	0=Negative	2=Grade II (intermediate)		0 = Negative			1=yes	0=no		2= Delayed surgery (>8 weeks); other than primary RT		0	2=Grade II (intermediate)		4	3=Stage IIA	2=Yes	1=Yes	1=Yes	0=No	0=No	0=No	0=No	0=No	3		2	0	X	3=Stage IIA	2=PR	3=Stable Disease	3=Stable Disease	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks		Mass	Mass	Mass	Mass	33	29	30	30	-12.12	-9.09	-9.09	3.45	3.45	0	1	Single uni-centric mass with well-defined margin	219169			224204					219163	219208		224200	219163	219208		
1067	04/16/2007	2647=U Alabama (Birmingham)	4= >50-60	White	9=Lost	739	9=A->Tp		0=No	5=Indeterminate, not 1 or 2 above	0=No		3=Grade III (high)	0 = Negative	0 = Negative	0=negative	2=FISH				4=No, Adverse Event							2=Yes	1=Yes	0=No	0=No	0=No	0=No	0=No	0=No	4.5		2	1	0	4=Stage IIB	2=PR	1=CR		2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks		Regonal	Regonal			77	60	0		-22.08	-100		-100			3	Area enhancement with irregular margins (WITH modularity)		219563								219557				219557		
1068	04/16/2007	372=U North Carolina at Chapel Hill	4= >50-60	White	7=Alive	1005	7=AC->Tp		0=No	5=Indeterminate, not 1 or 2 above	1=Yes	1=Positive	1=Grade I (low)	7 = Positive	6 = Positive	0=negative	1=IHC	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both		3.5	1=Grade I (low)	0	12	4=Indeterminate	2=Yes	1=Yes	1=Yes	0=No	1=Yes	0=No	1=Yes	0=No	6.5		3	0	0	4=Stage IIB	3=Stable Disease	3=Stable Disease	3=Stable Disease	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass		51	54	54		5.88	5.88		0			3	Area enhancement with irregular margins (WITH modularity)				225432					221145			225429	221145			225429
1069	04/16/2007	508=U Ca at San Francisco	4= >50-60	White	7=Alive	1043	16=AC-> TpTd 		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No		2=Grade II (intermediate)			0=negative	1=IHC											2=Yes	1=Yes	1=Yes	0=No	1=Yes	0=No	0=No	0=No	4		2	1	0	4=Stage IIB	3=Stable Disease	2=PR	1=CR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks		Mass	Mass	Mass	Mass	31	26	22	24	-16.13	-29.03	-22.58	-15.38	-7.69	9.09	3	Area enhancement with irregular margins (WITH modularity)	221341	221352		227882				227882	221335	221347		227879		221347		
1070	04/16/2007	508=U Ca at San Francisco	2= >30-40	Unknown	7=Alive	1048	6=AC->Td		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		3=Grade III (high)	3 = Positive	0 = Negative	0=negative	1=IHC	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both				0	13	1=Stage 0 (DCIS only)	2=Yes	1=Yes	1=Yes	0=No	1=Yes	0=No	0=No	0=No	4.5		2	0	0	3=Stage IIA	3=Stable Disease	2=PR	2=PR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks	0= Standard Therapy, q3 wks	Mass	Mass	Mass	Mass	56	50	21	19	-10.71	-62.5	-66.07	-58	-62	-9.52	4	Area enhancement with irregular margins (WITHOUT modularity)										221366				221366		
1071	04/16/2007	372=U North Carolina at Chapel Hill	2= >30-40	Black or African American	7=Alive	1012	7=AC->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		1=Grade I (low)	8 = Positive	7 = Positive	0=negative	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both				11	16	6=Stage IIIB	2=Yes	0=No	0=No	0=No	0=No	0=No	0=No	0=No	10		3	2	0	5=Stage IIIA	3=Stable Disease	2=PR	2=PR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks		Mass	Mass	Mass	Mass	126	130	139	19	3.17	10.32	-84.92	6.92	-85.38	-86.33	3	Area enhancement with irregular margins (WITH modularity)										221218				221218		
1072	04/16/2007	372=U North Carolina at Chapel Hill	4= >50-60	White	7=Alive	1113	7=AC->Tp		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	1=Yes	1=Positive	3=Grade III (high)	0 = Negative	0 = Negative	0=negative	1=IHC											2=Yes	1=Yes	0=No	0=No	1=Yes	0=No	0=No	0=No	4.5		2	0	X	3=Stage IIA	3=Stable Disease	2=PR	1=CR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass		Mass	Mass	64		60	53		-6.25	-17.19			-11.67	2	Multi-lobulated mass with well-defined margins									221235	221248		229758	221235	221248		
1073	04/16/2007	2647=U Alabama (Birmingham)	3= >40-50	White	7=Alive	184	7=AC->Tp		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No		2=Grade II (intermediate)			1=positive(Any 3+ or FISH ratio >= 2)	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both				0	8										6	4	3	1	0	5=Stage IIIA	3=Stable Disease		1=CR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	75	72	72	68	-4	-4	-9.33	0	-5.56	-5.56	3	Area enhancement with irregular margins (WITH modularity)	220071								220065	220268						
1074	04/16/2007	939=U Penn	2= >30-40	White	7=Alive	1086	7=AC->Tp		0=No		0=No		3=Grade III (high)					0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both				0	21		2=Yes	0=No	1=Yes	1=Yes	1=Yes	0=No	1=Yes	1=Yes	10	5	3	1	0	5=Stage IIIA	3=Stable Disease	2=PR	2=PR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Regonal	Regonal	Regonal	Regonal	153	139	114	5	-9.15	-25.49	-96.73	-17.99	-96.4	-95.61	3	Area enhancement with irregular margins (WITH modularity)	220456				220456	220547			220513	220541		224534	220513	220541		224534
1077	04/16/2007	508=U Ca at San Francisco	3= >40-50	White	7=Alive	1050	6=AC->Td		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		2=Grade II (intermediate)	8 = Positive	6 = Positive	1=positive(Any 3+ or FISH ratio >= 2)	1=IHC	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both				0	7		2=Yes	1=Yes	1=Yes	0=No	1=Yes	0=No	0=No	1=Yes	5	2.5	2	1	0	4=Stage IIB	1=CR	1=CR	1=CR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks	0= Standard Therapy, q3 wks	Mass	Mass	Mass	Mass	51	39	16	15	-23.53	-68.63	-70.59	-58.97	-61.54	-6.25	2	Multi-lobulated mass with well-defined margins	221399	221407			221399	221407			221393	221401			221393			
1078	04/16/2007	508=U Ca at San Francisco	2= >30-40	Native Hawaiian or Pacific Islander	7=Alive	1060	6=AC->Td		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		2=Grade II (intermediate)	7 = Positive	7 = Positive	0=negative	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both				0	1	1=Stage 0 (DCIS only)	2=Yes	0=No	0=No	0=No	1=Yes	0=No	1=Yes	0=No	6	1	3	1	0	5=Stage IIIA	2=PR	2=PR	1=CR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks	0= Standard Therapy, q3 wks	Mass	Mass	Mass	Mass	86	88	88	86	2.33	2.33	0	0	-2.27	-2.27	2	Multi-lobulated mass with well-defined margins	221415	221426							221409	221420			221409	221420		
1081	04/16/2007	540=Georgetown	5= >60-70	136	7=Alive	1084	1=AC			2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No		2=Grade II (intermediate)	0 = Negative		0=negative	2=FISH	0=no	1=yes		2= Delayed surgery (>8 weeks); other than primary RT		2.2	2=Grade II (intermediate)	7	10	5=Stage IIIA	2=Yes	0=No	0=No	1=Yes	0=No	0=No	1=Yes	0=No	6	1.5	3	1	0	5=Stage IIIA	3=Stable Disease		3=Stable Disease	1=Anthracycline Only Regimen	0= Standard Therapy, q3 wks		Mass	Mass			56	47		38	-16.07		-32.14		-19.15		3	Area enhancement with irregular margins (WITH modularity)	221732	222087							221726	222082		226727				226727
1082	04/16/2007	372=U North Carolina at Chapel Hill	3= >40-50	White	7=Alive	895	7=AC->Tp		0=No	5=Indeterminate, not 1 or 2 above	1=Yes	1=Positive	3=Grade III (high)	7 = Positive	5 = Positive	1=positive(Any 3+ or FISH ratio >= 2)	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		0.4		0	5	3=Stage IIA	2=Yes	0=No	0=No	0=No	1=Yes	0=No	1=Yes	0=No	6	1.5	3	1	0	5=Stage IIIA	3=Stable Disease	2=PR	2=PR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	87	87	50	45	0	-42.53	-48.28	-42.53	-48.28	-10	3	Area enhancement with irregular margins (WITH modularity)	221853				221853				221847	222202		230583	221847			
1083	04/16/2007	2647=U Alabama (Birmingham)	4= >50-60	White	7=Alive	172	7=AC->Tp		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No		4=Indeterminate	4 = Positive	0 = Negative	1=positive(Any 3+ or FISH ratio >= 2)	2=FISH	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both				5	9										10	2	3	1	0	5=Stage IIIA	3=Stable Disease		1=CR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Regonal	Regonal	Regonal		90	88	62	0	-2.22	-31.11	-100	-29.55	-100	-100	3	Area enhancement with irregular margins (WITH modularity)	221932								221926							
1084	04/16/2007	530=Mem Sloan-Kettering Cancer Ctr	2= >30-40	White	7=Alive	874	7=AC->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		3=Grade III (high)	8 = Positive	0 = Negative	1=positive(Any 3+ or FISH ratio >= 2)	2=FISH	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both			3=Grade III (high)	1	12	5=Stage IIIA	2=Yes	0=No	0=No	0=No	1=Yes	0=No	1=Yes	0=No	8	4	3	1	X	5=Stage IIIA	3=Stable Disease	2=PR		2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Regonal	111	120	31	24	8.11	-72.07	-78.38	-74.17	-80	-22.58	1	Single uni-centric mass with well-defined margin	222598	223238		238047	222598				222592	223232		227407	222592	223232		227407
1085	04/16/2007	540=Georgetown	3= >40-50	White	7=Alive	948	16=AC-> TpTd 		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No		2=Grade II (intermediate)	8 = Positive	5 = Positive	0=negative	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both				1	17		2=Yes	0=No	1=Yes	1=Yes	1=Yes	0=No	1=Yes	0=No	8	4	4	2	0	6=Stage IIIB	2=PR	2=PR	1=CR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks		Mass	Mass	Mass	Mass	90	63	25	29	-30	-72.22	-67.78	-60.32	-53.97	16	3	Area enhancement with irregular margins (WITH modularity)	224348								224343	224254			224343	224254		
1086	04/16/2007	530=Mem Sloan-Kettering Cancer Ctr	3= >40-50	Black or African American	7=Alive	861	6=AC->Td		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		3=Grade III (high)	4 = Positive	4 = Positive	1=positive(Any 3+ or FISH ratio >= 2)	2=FISH	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		2	2=Grade II (intermediate)	2	14	4=Indeterminate	2=Yes	0=No	0=No	1=Yes	1=Yes	0=No	1=Yes	0=No	9	3					2=PR		2=PR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	0= Standard Therapy, q3 wks	Mass	Mass	Mass	Mass	69	66	37	25	-4.35	-46.38	-63.77	-43.94	-62.12	-32.43	2	Multi-lobulated mass with well-defined margins	223231	225699							223224	225693		239404	223224	225693		
1087	04/16/2007	2647=U Alabama (Birmingham)	3= >40-50	White	7=Alive	715	7=AC->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No			0 = Negative	0 = Negative	1=positive(Any 3+ or FISH ratio >= 2)	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both				0	15		2=Yes	0=No	1=Yes	0=No	1=Yes	1=Yes	1=Yes	0=No	4	2	2	1	X	4=Stage IIB	3=Stable Disease	1=CR	1=CR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass			58	42		0	-27.59		-100		-100		2	Multi-lobulated mass with well-defined margins	222920				222920				222915							
1088	04/16/2007	508=U Ca at San Francisco	4= >50-60	White	7=Alive	1037	6=AC->Td		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		3=Grade III (high)	8 = Positive	7 = Positive	0=negative	1=IHC	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both				0	3	1=Stage 0 (DCIS only)	2=Yes	1=Yes	1=Yes	0=No	1=Yes	0=No	0=No	0=No	4.5	0.5	2	0	0	3=Stage IIA	3=Stable Disease	1=CR	1=CR	2=Anthracycline Plus Taxane		0= Standard Therapy, q3 wks	Mass	Mass	Mass		77	87	43	0	12.99	-44.16	-100	-50.57	-100	-100	2	Multi-lobulated mass with well-defined margins	226961								226957							
1089	04/16/2007	2790=ECOG	5= >60-70	Black or African American	7=Alive	983	1=AC		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No		2=Grade II (intermediate)	8 = Positive	6 = Positive	0=negative	2=FISH	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		2	2=Grade II (intermediate)	5	15	5=Stage IIIA	2=Yes	0=No	0=No	0=No	1=Yes	0=No	1=Yes	0=No	11	3	4	2	0	6=Stage IIIB	3=Stable Disease	2=PR	1=CR	1=Anthracycline Only Regimen	0= Standard Therapy, q3 wks	0= Standard Therapy, q3 wks	Regonal	Regonal	Regonal	Regonal	90	89	60	60	-1.11	-33.33	-33.33	-32.58	-32.58	0	4	Area enhancement with irregular margins (WITHOUT modularity)	228172	228184							228165	228178						
1090	04/16/2007	372=U North Carolina at Chapel Hill	4= >50-60	White	7=Alive	1009	7=AC->Tp		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No		2=Grade II (intermediate)	8 = Positive	4 = Positive	1=positive(Any 3+ or FISH ratio >= 2)	2=FISH	0=no	1=yes		2= Delayed surgery (>8 weeks); other than primary RT				0	23	1=Stage 0 (DCIS only)	2=Yes	0=No	0=No	0=No	1=Yes	0=No	1=Yes	1=Yes	6		4	0	0	6=Stage IIIB	3=Stable Disease	3=Stable Disease	3=Stable Disease	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	64	62	48	52	-3.13	-25	-18.75	-22.58	-16.13	8.33	3	Area enhancement with irregular margins (WITH modularity)		225585								225579				225579		
1091	04/16/2007	530=Mem Sloan-Kettering Cancer Ctr	4= >50-60	Asian	7=Alive	922	7=AC->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		3=Grade III (high)	0 = Negative	0 = Negative	1=positive(Any 3+ or FISH ratio >= 2)	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		1.7	3=Grade III (high)	3	10	3=Stage IIA	2=Yes	0=No	0=No	1=Yes	1=Yes	1=Yes	1=Yes	0=No	10.5	2					3=Stable Disease	2=PR	2=PR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	70	62	54	53	-11.43	-22.86	-24.29	-12.9	-14.52	-1.85	2	Multi-lobulated mass with well-defined margins	225707	225718		244234					225701	225712		239396				
1092	04/16/2007	508=U Ca at San Francisco	3= >40-50	White	7=Alive	1040	6=AC->Td		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		2=Grade II (intermediate)	7 = Positive	5 = Positive	0=negative	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		0.3	2=Grade II (intermediate)	0	21	2=Stage I	2=Yes	1=Yes	0=No	0=No	1=Yes	0=No	0=No	0=No		1	2	0	0	3=Stage IIA	3=Stable Disease	2=PR	1=CR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks	0= Standard Therapy, q3 wks	Mass	Mass	Mass		82	88	43	0	7.32	-47.56	-100	-51.14	-100	-100	2	Multi-lobulated mass with well-defined margins		226943								226937						
1093	04/16/2007	508=U Ca at San Francisco	4= >50-60	White	7=Alive	829	6=AC->Td		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No		2=Grade II (intermediate)	0 = Negative	0 = Negative	1=positive(Any 3+ or FISH ratio >= 2)	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		1.1	2=Grade II (intermediate)	0	13	2=Stage I	2=Yes	0=No	1=Yes	0=No	0=No	0=No	1=Yes	0=No	5		3	0	0	4=Stage IIB	3=Stable Disease	2=PR		2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks	0= Standard Therapy, q3 wks																									226915			229931				
1094	04/16/2007	508=U Ca at San Francisco	3= >40-50	White	7=Alive	537	6=AC->Td		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		1=Grade I (low)	8 = Positive	8 = Positive	0=negative	1=IHC	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both		6.3	3=Grade III (high)	4	11	5=Stage IIIA	2=Yes	1=Yes	1=Yes	0=No	0=No	0=No	0=No	0=No	8	2	3	1	X	5=Stage IIIA	3=Stable Disease	2=PR	2=PR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks	0= Standard Therapy, q3 wks	Regonal		Regonal	Regonal	91		61	55		-32.97	-39.56			-9.84	5	Septal spread; streaming	226899			230782								230779				
1095	04/16/2007	530=Mem Sloan-Kettering Cancer Ctr	3= >40-50	White	7=Alive	1015	15=EC->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		3=Grade III (high)	8 = Positive	8 = Positive	0=negative	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		3	2=Grade II (intermediate)	13	29	7=Stage IIIC	2=Yes	0=No	0=No	1=Yes	1=Yes	0=No	1=Yes	0=No	8		4	0	0	6=Stage IIIB	3=Stable Disease	2=PR	2=PR	2=Anthracycline Plus Taxane			Mass	Mass	Mass	Mass	76	67	56	54	-11.84	-26.32	-28.95	-16.42	-19.4	-3.57	1	Single uni-centric mass with well-defined margin	225737	225748		244238	225737				225731	225742		239398				
1096	04/16/2007	939=U Penn	3= >40-50	White	7=Alive	1018	7=AC->Tp		0=No		0=No		2=Grade II (intermediate)			1=positive(Any 3+ or FISH ratio >= 2)	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both				16	41	7=Stage IIIC	2=Yes	0=No	0=No	1=Yes	1=Yes	0=No	1=Yes	0=No	3.5	2.5	2	1	0	4=Stage IIB	3=Stable Disease	2=PR	1=CR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	44	36	27	27	-18.18	-38.64	-38.64	-25	-25	0	4	Area enhancement with irregular margins (WITHOUT modularity)					224298				224292	224525		228994	224292	224525		
1097	04/16/2007	939=U Penn	3= >40-50	White	7=Alive	1031	7=AC->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	1=Yes	1=Positive				0=negative	1=IHC	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both		0		0	7	1=Stage 0 (DCIS only)	2=Yes	1=Yes	1=Yes	1=Yes	1=Yes	0=No	0=No	0=No	5		2	1	0	4=Stage IIB	2=PR	1=CR	1=CR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	70	34	11	8	-51.43	-84.29	-88.57	-67.65	-76.47	-27.27	2	Multi-lobulated mass with well-defined margins									224273	224380						
1098	04/16/2007	2527=U Texas SW Med Ctr	5= >60-70	White	7=Alive	889	6=AC->Td		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	1=Yes	1=Positive		8 = Positive	2 = Negative	1=positive(Any 3+ or FISH ratio >= 2)	2=FISH	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both				0	20	5=Stage IIIA	2=Yes	1=Yes	1=Yes	0=No	1=Yes	0=No	0=No	0=No	5	1.9	2	2	X	5=Stage IIIA	3=Stable Disease	1=CR	1=CR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks	0= Standard Therapy, q3 wks	Mass	Mass	Mass		60	52	32	0	-13.33	-46.67	-100	-38.46	-100	-100	2	Multi-lobulated mass with well-defined margins		228238							228221	228232						
1099	04/16/2007	508=U Ca at San Francisco	4= >50-60	White	7=Alive	997	7=AC->Tp		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No		2=Grade II (intermediate)			0=negative	2=FISH	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both				0	11	1=Stage 0 (DCIS only)	2=Yes	1=Yes	1=Yes	0=No	1=Yes	0=No	0=No	0=No	9	0.8	3	1	X	5=Stage IIIA	2=PR	2=PR	1=CR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Regonal	Regonal	Regonal	Regonal	69	52	31	6	-24.64	-55.07	-91.3	-40.38	-88.46	-80.65	3	Area enhancement with irregular margins (WITH modularity)	226820								226814	226826						
1100	04/16/2007	508=U Ca at San Francisco	5= >60-70	White	7=Alive	959	6=AC->Td		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No		2=Grade II (intermediate)	8 = Positive	0 = Negative	0=negative	2=FISH	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both		2.1	2=Grade II (intermediate)	0	2	3=Stage IIA	2=Yes	1=Yes	1=Yes	0=No	0=No	0=No	0=No	0=No	4		2	0	X	3=Stage IIA	3=Stable Disease	1=CR	1=CR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks	0= Standard Therapy, q3 wks	Mass	Mass	Mass	Mass	36	31	20	15	-13.89	-44.44	-58.33	-35.48	-51.61	-25	3	Area enhancement with irregular margins (WITH modularity)	226791	226802			226791				226785	226796		234954				
1101	04/16/2007	508=U Ca at San Francisco	3= >40-50	Black or African American	7=Alive	658	1=AC		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No			0 = Negative	0 = Negative	2=indeterminate(2+)	1=IHC	0=no	1=yes		2= Delayed surgery (>8 weeks); other than primary RT		5.6		8	29	5=Stage IIIA									11	2	3	1	0	5=Stage IIIA	3=Stable Disease	1=CR	2=PR	1=Anthracycline Only Regimen	0= Standard Therapy, q3 wks		Regonal	Regonal		Regonal	89	38		80	-57.3		-10.11		110.53		5	Septal spread; streaming		233901				233901			226758	226769		229935				
1102	04/16/2007	2647=U Alabama (Birmingham)	4= >50-60	Black or African American	7=Alive	215	7=AC->Tp		0=No		0=No		3=Grade III (high)	8 = Positive	0 = Negative	1=positive(Any 3+ or FISH ratio >= 2)	1=IHC	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both		0	3=Grade III (high)	14	14	5=Stage IIIA										2							1=CR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks		Regonal	Regonal	Regonal	Regonal	113	126	110	121	11.5	-2.65	7.08	-12.7	-3.97	10	5	Septal spread; streaming	225022								225016	225079						
1103	04/16/2007	372=U North Carolina at Chapel Hill	4= >50-60	White	7=Alive	937	7=AC->Tp		1=Yes	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No		3=Grade III (high)	0 = Negative	0 = Negative	1=positive(Any 3+ or FISH ratio >= 2)	1=IHC	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both				0	10	1=Stage 0 (DCIS only)									9		4	2	0	6=Stage IIIB	3=Stable Disease	2=PR		2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	100	100	26	17	0	-74	-83	-74	-83	-34.62	1	Single uni-centric mass with well-defined margin		225648			225635				225629	225643			225629			
1104	04/16/2007	2527=U Texas SW Med Ctr	4= >50-60	Black or African American	7=Alive	952	6=AC->Td		0=No	5=Indeterminate, not 1 or 2 above	1=Yes	0=Negative		1 = Negative	2 = Negative	1=positive(Any 3+ or FISH ratio >= 2)	3=Other	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both				0	10	1=Stage 0 (DCIS only)	2=Yes	1=Yes	1=Yes	0=No	0=No	0=No	0=No	0=No	5		2	1	0	4=Stage IIB	2=PR	1=CR	1=CR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks	0= Standard Therapy, q3 wks	Mass	Mass	Mass		52	48	24	31	-7.69	-53.85	-40.38	-50	-35.42	29.17	2	Multi-lobulated mass with well-defined margins	228257	228268		240961	228257	228268			228251	228262						
1106	04/16/2007	2527=U Texas SW Med Ctr	4= >50-60	Unknown	7=Alive	914	7=AC->Tp		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	1=Yes	1=Positive		8 = Positive	7 = Positive	0=negative	2=FISH	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		3.3	3=Grade III (high)	0	11	4=Indeterminate	2=Yes	0=No	0=No	0=No	1=Yes	0=No	1=Yes	0=No	6		4	1	0	6=Stage IIIB	3=Stable Disease	3=Stable Disease	2=PR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	60	56	56	41	-6.67	-6.67	-31.67	0	-26.79	-26.79	1	Single uni-centric mass with well-defined margin	228305						240962		228300			239285				
1107	04/16/2007	2647=U Alabama (Birmingham)	4= >50-60	White	7=Alive	235	7=AC->Tp		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	1=Yes	0=Negative	2=Grade II (intermediate)			2=indeterminate(2+)	1=IHC	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both		0	2=Grade II (intermediate)		5										3		2	0	X		2=PR		1=CR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	24	22	20	20	-8.33	-16.67	-16.67	-9.09	-9.09	0	1	Single uni-centric mass with well-defined margin	225346			230960	225347	225425		230960	225340	225419		230957				
1109	04/16/2007	2647=U Alabama (Birmingham)	4= >50-60	White	7=Alive	197	7=AC->Tp		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	1=Yes	0=Negative	2=Grade II (intermediate)	8 = Positive		1=positive(Any 3+ or FISH ratio >= 2)	2=FISH	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both			3=Grade III (high)		1										2.5		2	0	0		3=Stable Disease	1=CR	1=CR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	0= Standard Therapy, q3 wks	Mass	Mass	Mass	Mass	28	23	16	20	-17.86	-42.86	-28.57	-30.43	-13.04	25	2	Multi-lobulated mass with well-defined margins	225624			231178	225624, 225625	225675			225618	225669		231175				
1110	04/16/2007	530=Mem Sloan-Kettering Cancer Ctr	4= >50-60	White	7=Alive	957	16=AC-> TpTd 		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No		3=Grade III (high)	7 = Positive	7 = Positive	0=negative	1=IHC	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both		1.2	2=Grade II (intermediate)	1	4	3=Stage IIA	2=Yes	1=Yes	1=Yes	0=No	0=No	0=No	0=No	0=No	6						3=Stable Disease	2=PR	1=CR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks		Mass	Mass	Mass	Mass	36	36	21	13	0	-41.67	-63.89	-41.67	-63.89	-38.1	1	Single uni-centric mass with well-defined margin	227422	227433		238048	227422, 227423	227433		238048	227417	227427		239418				
1111	04/16/2007	530=Mem Sloan-Kettering Cancer Ctr	4= >50-60	White	7=Alive	896	7=AC->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		2=Grade II (intermediate)	8 = Positive	8 = Positive	0=negative	2=FISH	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both			3=Grade III (high)	2	25	5=Stage IIIA	2=Yes	0=No	0=No	0=No	1=Yes	0=No	1=Yes	0=No	7	1.5	3	1	0	5=Stage IIIA	3=Stable Disease	3=Stable Disease	3=Stable Disease	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Regonal	Regonal	Regonal	Regonal	78	79	77	78	1.28	-1.28	0	-2.53	-1.27	1.3	3	Area enhancement with irregular margins (WITH modularity)	227443			244236					227438	227448		239413				
1112	04/16/2007	2647=U Alabama (Birmingham)	3= >40-50	White	7=Alive	183	7=AC->Tp		0=No	5=Indeterminate, not 1 or 2 above	0=No		3=Grade III (high)	0 = Negative	0 = Negative	1=positive(Any 3+ or FISH ratio >= 2)	3=Other	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both				0	8										3.5	2	2	1	0	4=Stage IIB		2=PR	1=CR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Regonal		Regonal	Regonal	71	78	58	5	9.86	-18.31	-92.96	-25.64	-93.59	-91.38	5	Septal spread; streaming	225865			231124	225865, 225866	225965			225859	225960						
1113	04/16/2007	2647=U Alabama (Birmingham)	4= >50-60	White	7=Alive	712	7=AC->Tp		0=No	5=Indeterminate, not 1 or 2 above	0=No		4=Indeterminate	8 = Positive	5 = Positive	0=negative	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		0	2=Grade II (intermediate)	0	9	2=Stage I									5	2						2=PR	1=CR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks		Mass	Mass		25	25	24	0	0	-4	-100	-4	-100	-100	3	Area enhancement with irregular margins (WITH modularity)	226217			231498		226334			226211	226328		231495				
1114	04/16/2007	372=U North Carolina at Chapel Hill	3= >40-50	Black or African American	7=Alive	775	9=A->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		2=Grade II (intermediate)	6 = Positive	7 = Positive	0=negative	2=FISH	0=no	1=yes		2= Delayed surgery (>8 weeks); other than primary RT		1.2	3=Grade III (high)	0	22	3=Stage IIA									6	1	4	1	0	6=Stage IIIB	3=Stable Disease	2=PR		2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	60	50	45	45	-16.67	-25	-25	-10	-10	0	4	Area enhancement with irregular margins (WITHOUT modularity)	226662	226676			226662	226676			226658	226670		232136				
1115	04/16/2007	939=U Penn	4= >50-60	White	7=Alive	922	6=AC->Td		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No		2=Grade II (intermediate)	6 = Positive	3 = Positive	1=positive(Any 3+ or FISH ratio >= 2)	2=FISH	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both				0	10	1=Stage 0 (DCIS only)	2=Yes	1=Yes	0=No	1=Yes	1=Yes	0=No	0=No	0=No	10	2					2=PR	1=CR	1=CR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks	1= Dose Dense Therapy, q2 wks	Regonal	Regonal	Regonal		184	145	95	0	-21.2	-48.37	-100	-34.48	-100	-100	5	Septal spread; streaming				231403	225982	226032			225975	226026				226026		
1116	04/16/2007	2647=U Alabama (Birmingham)	2= >30-40	White	7=Alive	699	7=AC->Tp		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No		4=Indeterminate	8 = Positive	8 = Positive	0=negative	2=FISH	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both			2=Grade II (intermediate)	7	9		2=Yes	0=No	1=Yes	0=No	1=Yes	0=No	1=Yes	0=No	4	2	1	1	X	3=Stage IIA		1=CR	1=CR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	26	30	7	42	15.38	-73.08	61.54	-76.67	40	500	3	Area enhancement with irregular margins (WITH modularity)	226366			231670					226360	226445		231667				
1117	04/16/2007	508=U Ca at San Francisco	3= >40-50	Black or African American	7=Alive	881	6=AC->Td		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No		1=Grade I (low)	7 = Positive	8 = Positive	0=negative	1=IHC	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both		4.1	1=Grade I (low)	0	1	3=Stage IIA	2=Yes	1=Yes	1=Yes	0=No	1=Yes	0=No	0=No	0=No	4.5	1	2	1	0	4=Stage IIB	3=Stable Disease	2=PR	2=PR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks	0= Standard Therapy, q3 wks	Mass	Mass	Mass	Mass	68	65	38	20	-4.41	-44.12	-70.59	-41.54	-69.23	-47.37	2	Multi-lobulated mass with well-defined margins		226749										234956				
1120	04/16/2007	508=U Ca at San Francisco	3= >40-50	Black or African American	9=Lost	540	7=AC->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		1=Grade I (low)	8 = Positive	8 = Positive	0=negative	1=IHC				5=No, Patient Refusal															3.3		2	0	0	3=Stage IIA	2=PR	3=Stable Disease	1=CR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks		Mass	Mass	Mass		74	48	39		-35.14	-47.3		-18.75			1	Single uni-centric mass with well-defined margin	227348								227342							
1121	04/16/2007	2647=U Alabama (Birmingham)	3= >40-50	White	7=Alive	192	7=AC->Tp		0=No	5=Indeterminate, not 1 or 2 above	0=No		4=Indeterminate	0 = Negative	0 = Negative	0=negative	1=IHC	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both				0	15										3	1	2	1	X	4=Stage IIB	1=CR	1=CR	1=CR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass		31	23	17	0	-25.81	-45.16	-100	-26.09	-100	-100	1	Single uni-centric mass with well-defined margin	226721			231990				231990	226715	226852						
1122	04/16/2007	2647=U Alabama (Birmingham)	4= >50-60	White	7=Alive	172	7=AC->Tp		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No		3=Grade III (high)			1=positive(Any 3+ or FISH ratio >= 2)	2=FISH	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both				1	9	3=Stage IIA									5	3	1	0	X		3=Stable Disease		1=CR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Regonal	Regonal	Regonal	Regonal	65	53	56	25	-18.46	-13.85	-61.54	5.66	-52.83	-55.36			227021				227021, 227022				227015	227036						
1123	04/16/2007	2647=U Alabama (Birmingham)	5= >60-70	White	7=Alive	203	7=AC->Tp		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No		4=Indeterminate			2=indeterminate(2+)	2=FISH	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		0		13	21	5=Stage IIIA									8	5					2=PR		1=CR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	85	61	60	48	-28.24	-29.41	-43.53	-1.64	-21.31	-20	4	Area enhancement with irregular margins (WITHOUT modularity)	227156			232629				227223	227150	227217		232626				
1124	04/16/2007	2527=U Texas SW Med Ctr	3= >40-50	White	7=Alive	831	7=AC->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	1=Yes	1=Positive	2=Grade II (intermediate)	0 = Negative	0 = Negative			0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		6.5	3=Grade III (high)	0	15	5=Stage IIIA	2=Yes	0=No	1=Yes	0=No	1=Yes	1=Yes	1=Yes	0=No	8		3	0	0	4=Stage IIB	3=Stable Disease	4=Progressive Disease	3=Stable Disease	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	100	95	95	82	-5	-5	-18	0	-13.68	-13.68	3	Area enhancement with irregular margins (WITH modularity)		228336							228319	228330		239239				
1126	04/16/2007	2051=U Wash	5= >60-70	White	7=Alive	536	1=AC		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No		2=Grade II (intermediate)	0 = Negative	0 = Negative	0=negative	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both				0	9	6=Stage IIIB	2=Yes	0=No	0=No	0=No	0=No	0=No	0=No	0=No	7.5	4	4	2	X	6=Stage IIIB	2=PR		1=CR	1=Anthracycline Only Regimen			Mass	Mass		Regonal	105	92		70	-12.38		-33.33		-23.91		3	Area enhancement with irregular margins (WITH modularity)	227329								227323	227673			227323			
1127	04/16/2007	508=U Ca at San Francisco	3= >40-50	Asian	7=Alive	575	7=AC->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		2=Grade II (intermediate)	8 = Positive	8 = Positive	2=indeterminate(2+)	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		1.5	1=Grade I (low)	2	9	3=Stage IIA	2=Yes	1=Yes	1=Yes	0=No	1=Yes	0=No	0=No	0=No	3.5		2	0	0		3=Stable Disease	2=PR	2=PR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	53	62	52	36	16.98	-1.89	-32.08	-16.13	-41.94	-30.77	1	Single uni-centric mass with well-defined margin	227534	227545				227545			227528	227539						
1128	04/16/2007	508=U Ca at San Francisco	2= >30-40	White	7=Alive	794	6=AC->Td		0=No									1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both		8.3	1=Grade I (low)	0	7	3=Stage IIA									3	2	2	1	0	4=Stage IIB	2=PR	2=PR	2=PR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks	0= Standard Therapy, q3 wks	Mass	Mass	Mass	Mass	23	22	15	12	-4.35	-34.78	-47.83	-31.82	-45.45	-20	1	Single uni-centric mass with well-defined margin	227623				227624				227617			236460				
1129	04/16/2007	530=Mem Sloan-Kettering Cancer Ctr	4= >50-60	Black or African American	8=Dead	619	7=AC->Tp		0=No	5=Indeterminate, not 1 or 2 above	0=No		3=Grade III (high)	0 = Negative	0 = Negative	1=positive(Any 3+ or FISH ratio >= 2)	2=FISH	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both				0	13	1=Stage 0 (DCIS only)	2=Yes	0=No	0=No	1=Yes	1=Yes	1=Yes	1=Yes	0=No	11		3	1	X	5=Stage IIIA	3=Stable Disease	2=PR	1=CR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Regonal		80	60	50	0	-25	-37.5	-100	-16.67	-100	-100	3	Area enhancement with irregular margins (WITH modularity)	235680			244235	235681				235674	235682						
1130	04/16/2007	2647=U Alabama (Birmingham)	2= >30-40	White	7=Alive	200	7=AC->Tp		0=No	5=Indeterminate, not 1 or 2 above	1=Yes	0=Negative	3=Grade III (high)	3 = Positive	0 = Negative	0=negative	2=FISH	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both						1=Stage 0 (DCIS only)									4.6		2	0	X	3=Stage IIA	2=PR		1=CR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass		22	9	9	0	-59.09	-59.09	-100	0	-100	-100	1	Single uni-centric mass with well-defined margin	227837				227837, 227838	227916			227831	227911						
1132	04/16/2007	508=U Ca at San Francisco	4= >50-60	White	7=Alive	896	7=AC->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		1=Grade I (low)	8 = Positive	8 = Positive	0=negative	1=IHC	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both		4.5	1=Grade I (low)	1	13	4=Indeterminate	2=Yes	1=Yes	1=Yes	0=No	1=Yes	0=No	0=No	0=No	5		2	0	0	3=Stage IIA		2=PR		2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	65	64	60	52	-1.54	-7.69	-20	-6.25	-18.75	-13.33	4	Area enhancement with irregular margins (WITHOUT modularity)	229122	229133							229116	229128		232855				
1134	04/16/2007	508=U Ca at San Francisco	3= >40-50	White	7=Alive	823	7=AC->Tp		0=No									1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both		4.9	2=Grade II (intermediate)	1	14	4=Indeterminate	2=Yes	1=Yes	1=Yes	0=No	1=Yes	0=No	0=No	1=Yes	5	1	2	1	0	4=Stage IIB	3=Stable Disease	1=CR	2=PR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	38	41	21	15	7.89	-44.74	-60.53	-48.78	-63.41	-28.57	2	Multi-lobulated mass with well-defined margins	229103			232040				232040	229097	229109		232037				
1135	04/16/2007	508=U Ca at San Francisco	4= >50-60	White	7=Alive	746	6=AC->Td		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No		3=Grade III (high)	0 = Negative	0 = Negative	0=negative	1=IHC	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both		2.2	3=Grade III (high)	21	33	7=Stage IIIC	2=Yes	1=Yes	0=No	0=No	1=Yes	0=No	0=No	0=No	3	2.5	2	1	0	4=Stage IIB	3=Stable Disease	4=Progressive Disease	2=PR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks	0= Standard Therapy, q3 wks	Mass	Mass	Mass	Mass	28	28	21	11	0	-25	-60.71	-25	-60.71	-47.62	1	Single uni-centric mass with well-defined margin	229141			234531	229141	229152		234531	229136	229146		234528				
1136	04/16/2007	2647=U Alabama (Birmingham)	5= >60-70	Black or African American	8=Dead	497	7=AC->Tp		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No		3=Grade III (high)	0 = Negative	0 = Negative	0=negative	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		0	3=Grade III (high)	5	10	5=Stage IIIA	2=Yes	0=No	1=Yes	1=Yes	1=Yes	1=Yes	1=Yes	0=No	6	6	3	1	X	5=Stage IIIA	3=Stable Disease	1=CR	1=CR	2=Anthracycline Plus Taxane		1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	82	70	28	44	-14.63	-65.85	-46.34	-60	-37.14	57.14	4	Area enhancement with irregular margins (WITHOUT modularity)	229274			233586	229274	229411			229268	229406		233583				
1137	04/16/2007	508=U Ca at San Francisco	1=  18-30	White	7=Alive	780	20=EC ->Tp-> Carboplatin		1=Yes	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		2=Grade II (intermediate)	7 = Positive	7 = Positive	1=positive(Any 3+ or FISH ratio >= 2)	2=FISH	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both				1	8	3=Stage IIA	2=Yes	0=No	0=No	0=No	1=Yes	0=No	1=Yes	0=No	10	2	3	1	0	5=Stage IIIA	3=Stable Disease	2=PR	1=CR	4=Anthracycline + Taxane + Other	0= Standard Therapy, q3 wks		Regonal	Regonal	Regonal	Regonal	92	90	34	25	-2.17	-63.04	-72.83	-62.22	-72.22	-26.47	3	Area enhancement with irregular margins (WITH modularity)									229500	229511						
1138	04/16/2007	2647=U Alabama (Birmingham)	2= >30-40	Black or African American	7=Alive	719	7=AC->Tp		0=No	5=Indeterminate, not 1 or 2 above	0=No		4=Indeterminate		0 = Negative	0=negative	2=FISH	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both				0	10		2=Yes	0=No	1=Yes	0=No	1=Yes	1=Yes	1=Yes	0=No	6		3	1	0	5=Stage IIIA	3=Stable Disease	2=PR	2=PR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	63	41	45	39	-34.92	-28.57	-38.1	9.76	-4.88	-13.33	2	Multi-lobulated mass with well-defined margins	229567				229567	229595			229561	229589						
1139	04/16/2007	939=U Penn	3= >40-50	White	7=Alive	903	7=AC->Tp		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	1=Yes	1=Positive	2=Grade II (intermediate)	0 = Negative	0 = Negative	0=negative	3=Other	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both				0	12	1=Stage 0 (DCIS only)	2=Yes	1=Yes	0=No	0=No	0=No	0=No	0=No	1=Yes	11		3	1	0	5=Stage IIIA	3=Stable Disease	1=CR	1=CR	2=Anthracycline Plus Taxane		1= Dose Dense Therapy, q2 wks	Regonal	Regonal			113	113	6	0	0	-94.69	-100	-94.69	-100	-100	4	Area enhancement with irregular margins (WITHOUT modularity)	229432			232983	229433				229426	229548						
1140	04/16/2007	508=U Ca at San Francisco	2= >30-40	White	7=Alive	866	21=FEC->Tp->Abraxane		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		2=Grade II (intermediate)	7 = Positive	0 = Negative	0=negative	2=FISH	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		1	3=Grade III (high)	9	14	5=Stage IIIA	2=Yes	0=No	0=No	0=No	0=No	0=No	0=No	0=No	18	5	3	1	0	5=Stage IIIA	2=PR	2=PR	1=CR	4=Anthracycline + Taxane + Other	0= Standard Therapy, q3 wks		Regonal	Regonal			118	37		0	-68.64		-100		-100		5	Septal spread; streaming									229872	229883						
1141	04/16/2007	530=Mem Sloan-Kettering Cancer Ctr	3= >40-50	Black or African American	7=Alive	769	7=AC->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		2=Grade II (intermediate)					0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		2.5	3=Grade III (high)	0	22	3=Stage IIA	2=Yes	0=No	0=No	0=No	1=Yes	0=No	1=Yes	0=No	8		3	3	0	7=Stage IIIC	4=Progressive Disease	2=PR	2=PR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Regonal		Mass	Mass	90	81	67	47	-10	-25.56	-47.78	-17.28	-41.98	-29.85	4	Area enhancement with irregular margins (WITHOUT modularity)				244240	235704				235698							
1143	04/16/2007	540=Georgetown	4= >50-60	White	7=Alive	687	7=AC->Tp		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No		3=Grade III (high)	8 = Positive	5 = Positive	0=negative	2=FISH	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both			2=Grade II (intermediate)	5	22	4=Indeterminate	2=Yes	1=Yes	1=Yes	0=No	1=Yes	0=No	0=No	0=No	7		3	1	0	5=Stage IIIA	4=Progressive Disease	2=PR	2=PR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass		92	89	77		-3.26	-16.3		-13.48			3	Area enhancement with irregular margins (WITH modularity)				233850					230007							
1147	04/16/2007	508=U Ca at San Francisco	4= >50-60	White	7=Alive	776	7=AC->Tp		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No		2=Grade II (intermediate)					1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both		2.4	3=Grade III (high)	2	14	4=Indeterminate	2=Yes	1=Yes	0=No	1=Yes	1=Yes	1=Yes	0=No	0=No	7	1	3	1	X	5=Stage IIIA	3=Stable Disease			2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	63	42	22	9	-33.33	-65.08	-85.71	-47.62	-78.57	-59.09	2	Multi-lobulated mass with well-defined margins	231230								231224							
1148	04/16/2007	939=U Penn	4= >50-60	White	7=Alive	694	16=AC-> TpTd 		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No		2=Grade II (intermediate)	0 = Negative	0 = Negative	1=positive(Any 3+ or FISH ratio >= 2)	1=IHC	1=yes	0=no		2= Delayed surgery (>8 weeks); other than primary RT				0	16	1=Stage 0 (DCIS only)	2=Yes	1=Yes	0=No	1=Yes	1=Yes	0=No	0=No	1=Yes	4.5	2	3	1	0	5=Stage IIIA	3=Stable Disease	2=PR		2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks		Mass	Mass	Mass		47	39	35	0	-17.02	-25.53	-100	-10.26	-100	-100	2	Multi-lobulated mass with well-defined margins	231387				231387				231381							
1149	04/16/2007	939=U Penn	4= >50-60	White	7=Alive	704	7=AC->Tp		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No							0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		3	3=Grade III (high)	7	14	5=Stage IIIA	2=Yes	0=No	0=No	0=No	1=Yes	0=No	1=Yes	0=No	13	4.5					2=PR	2=PR	2=PR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Regonal	Regonal			95	45	58	22	-52.63	-38.95	-76.84	28.89	-51.11	-62.07	5	Septal spread; streaming	231660			235289	231660			235289	231654							
1150	04/16/2007	939=U Penn	4= >50-60	White	7=Alive	656	7=AC->Tp			2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	1=Yes	1=Positive	4=Indeterminate	8 = Positive	7 = Positive	0=negative	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		1.5	4=Indeterminate	0	18	2=Stage I	2=Yes	1=Yes	0=No	0=No	0=No	0=No	1=Yes	0=No	5		3	1	0	5=Stage IIIA	3=Stable Disease	2=PR	2=PR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks		Mass	Mass		Mass	76	74	63	61	-2.63	-17.11	-19.74	-14.86	-17.57	-3.17	3	Area enhancement with irregular margins (WITH modularity)	231480			235424	231480			235424	231474							
1151	04/16/2007	939=U Penn	4= >50-60	Black or African American	7=Alive	650	7=AC->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		2=Grade II (intermediate)	8 = Positive	2 = Negative	1=positive(Any 3+ or FISH ratio >= 2)	2=FISH	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		0.7	4=Indeterminate	4	11	6=Stage IIIB	2=Yes	1=Yes	0=No	1=Yes	1=Yes	0=No	1=Yes	0=No	7	3					3=Stable Disease	2=PR	3=Stable Disease	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Regonal	Regonal	Regonal	Mass	165	156	113	37	-5.45	-31.52	-77.58	-27.56	-76.28	-67.26	3	Area enhancement with irregular margins (WITH modularity)	231535				231535				231529							
1152	04/16/2007	508=U Ca at San Francisco	4= >50-60	White	7=Alive	698	7=AC->Tp		1=Yes	5=Indeterminate, not 1 or 2 above	0=No		2=Grade II (intermediate)			1=positive(Any 3+ or FISH ratio >= 2)	2=FISH	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both		3.8	1=Grade I (low)	1	15	4=Indeterminate	2=Yes	1=Yes	0=No	0=No	1=Yes	0=No	0=No	0=No	6		3	1	0	5=Stage IIIA	2=PR	2=PR	2=PR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks		Regonal	Regonal	Regonal	Regonal	70	66	57	34	-5.71	-18.57	-51.43	-13.64	-48.48	-40.35	4	Area enhancement with irregular margins (WITHOUT modularity)	231760								231751							
1155	04/16/2007	939=U Penn	3= >40-50	White	7=Alive	706	7=AC->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	1=Yes	0=Negative	3=Grade III (high)	0 = Negative				0=no	1=yes		2= Delayed surgery (>8 weeks); other than primary RT					3	1=Stage 0 (DCIS only)	2=Yes	0=No	0=No	0=No	0=No	0=No	1=Yes	0=No	5						2=PR	1=CR	1=CR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks		Mass	Mass	Mass	Mass	87	71	79	61	-18.39	-9.2	-29.89	11.27	-14.08	-22.78	4	Area enhancement with irregular margins (WITHOUT modularity)	231867				231867				231861							
1156	04/16/2007	372=U North Carolina at Chapel Hill	5= >60-70	White	7=Alive	574	6=AC->Td		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No		3=Grade III (high)	0 = Negative	0 = Negative	1=positive(Any 3+ or FISH ratio >= 2)	4=Unknown	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		0		0	20	1=Stage 0 (DCIS only)	2=Yes	0=No	0=No	0=No	1=Yes	1=Yes	1=Yes	1=Yes	11	1.5	4	1	0	6=Stage IIIB	3=Stable Disease	2=PR	1=CR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Regonal	Regonal	Regonal		70	66	54	0	-5.71	-22.86	-100	-18.18	-100	-100	3	Area enhancement with irregular margins (WITH modularity)					232147				232141							
1157	04/16/2007	508=U Ca at San Francisco	3= >40-50	White	7=Alive	722	6=AC->Td		1=Yes	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		1=Grade I (low)	0 = Negative	0 = Negative	1=positive(Any 3+ or FISH ratio >= 2)	2=FISH	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both		0.5	2=Grade II (intermediate)	0	9	2=Stage I	2=Yes	1=Yes	1=Yes	0=No	1=Yes	0=No	0=No	0=No	5	2	3	1		5=Stage IIIA			1=CR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks	0= Standard Therapy, q3 wks	Mass	Mass	Mass	Mass	61	63	33	33	3.28	-45.9	-45.9	-47.62	-47.62	0	2	Multi-lobulated mass with well-defined margins									232407							
1158	04/16/2007	508=U Ca at San Francisco	5= >60-70	White	7=Alive	715	6=AC->Td		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No		2=Grade II (intermediate)	8 = Positive	8 = Positive	0=negative	1=IHC	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both		0.5	2=Grade II (intermediate)	1	3	3=Stage IIA	2=Yes	1=Yes	0=No	0=No	0=No	0=No	0=No	0=No	4		2	0	0	3=Stage IIA			2=PR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks	0= Standard Therapy, q3 wks	Mass	Mass	Mass	Mass	28	19	11		-32.14	-60.71		-42.11			1	Single uni-centric mass with well-defined margin	232060								232054							
1160	04/16/2007	2051=U Wash	4= >50-60	White	7=Alive	328	23=AC->Tp->Vinorelbine->Tarcena		0=No	5=Indeterminate, not 1 or 2 above	0=No		3=Grade III (high)	0 = Negative	0 = Negative	0=negative	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		4	3=Grade III (high)	10	37	5=Stage IIIA	2=Yes	0=No	0=No	0=No	1=Yes	0=No	1=Yes	0=No		4	3	1	0			4=Progressive Disease	4=Progressive Disease	4=Anthracycline + Taxane + Other			Mass	Mass		Mass	77	72		38	-6.49		-50.65		-47.22		3	Area enhancement with irregular margins (WITH modularity)	232339			249677				249677	232333							
1162	04/16/2007	939=U Penn	4= >50-60	Black or African American	7=Alive	721	16=AC-> TpTd 		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		2=Grade II (intermediate)			1=positive(Any 3+ or FISH ratio >= 2)	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both				4	13	5=Stage IIIA	2=Yes	0=No	0=No	0=No	0=No	0=No	0=No	0=No	12	3	3	3	0	7=Stage IIIC	3=Stable Disease	3=Stable Disease	2=PR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks		Regonal	Regonal	Regonal	Regonal	101	86	69	15	-14.85	-31.68	-85.15	-19.77	-82.56	-78.26	4	Area enhancement with irregular margins (WITHOUT modularity)	232838								232832							
1164	04/16/2007	939=U Penn	5= >60-70	White	7=Alive	678	6=AC->Td		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No					2=indeterminate(2+)	1=IHC	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both		0.5	4=Indeterminate	0	20	2=Stage I	2=Yes	1=Yes	1=Yes	0=No	0=No	0=No	0=No	0=No	6	2.5	3	1	0		3=Stable Disease	2=PR	1=CR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks	0= Standard Therapy, q3 wks	Mass	Mass	Mass	Mass	35	31	31	10	-11.43	-11.43	-71.43	0	-67.74	-67.74	1	Single uni-centric mass with well-defined margin	232500			238708	232500			238708	232494							
1165	04/16/2007	2527=U Texas SW Med Ctr	2= >30-40	White	7=Alive	639	7=AC->Tp		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No		3=Grade III (high)	0 = Negative	1 = Negative	0=negative	2=FISH	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		1	3=Grade III (high)	0	15		2=Yes	0=No	0=No	0=No	1=Yes	0=No	1=Yes	0=No	8	1.8	3	1		5=Stage IIIA	3=Stable Disease	2=PR	2=PR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	88	75	70	7	-14.77	-20.45	-92.05	-6.67	-90.67	-90	2	Multi-lobulated mass with well-defined margins	240971								239247							
1167	04/16/2007	2051=U Wash	4= >50-60	White	7=Alive	348	7=AC->Tp		1=Yes	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)			3=Grade III (high)			1=positive(Any 3+ or FISH ratio >= 2)	2=FISH	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		3.5		3	19	5=Stage IIIA									10.2		3	2	0	5=Stage IIIA	3=Stable Disease	2=PR	2=PR	2=Anthracycline Plus Taxane			Regonal	Mass	Mass	Mass	102	96	17	7	-5.88	-83.33	-93.14	-82.29	-92.71	-58.82	3	Area enhancement with irregular margins (WITH modularity)				249675				249675	233835							
1168	04/16/2007	508=U Ca at San Francisco	3= >40-50	White	8=Dead	347	16=AC-> TpTd 		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		3=Grade III (high)	0 = Negative	0 = Negative	0=negative	2=FISH	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both		3.6	2=Grade II (intermediate)	2	9	4=Indeterminate	2=Yes	0=No	0=No	0=No	0=No	0=No	0=No	0=No	4	2	2	1	0	4=Stage IIB	2=PR	2=PR	1=CR	2=Anthracycline Plus Taxane			Mass	Mass	Mass	Mass	36	36	24	39	0	-33.33	8.33	-33.33	8.33	62.5	2	Multi-lobulated mass with well-defined margins									234519							
1169	04/16/2007	372=U North Carolina at Chapel Hill	3= >40-50	White	7=Alive	552	7=AC->Tp		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	1=Yes	1=Positive	3=Grade III (high)	0 = Negative	0 = Negative	0=negative	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		2	3=Grade III (high)	13	18	7=Stage IIIC	2=Yes	0=No	1=Yes	1=Yes	1=Yes	0=No	1=Yes	0=No	10	7	3	2	0	5=Stage IIIA	2=PR	2=PR	2=PR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	82	82	70	42	0	-14.63	-48.78	-14.63	-48.78	-40	2	Multi-lobulated mass with well-defined margins	235184			239346	235184			239346	235178							
1171	04/16/2007	508=U Ca at San Francisco	4= >50-60	White	7=Alive	443	7=AC->Tp		1=Yes	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		2=Grade II (intermediate)	0 = Negative	0 = Negative	1=positive(Any 3+ or FISH ratio >= 2)	1=IHC											2=Yes	1=Yes	1=Yes	0=No	1=Yes	0=No	0=No	0=No	4	4	2	1	0	4=Stage IIB	3=Stable Disease	2=PR	1=CR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass		48	34	31	16	-29.17	-35.42	-66.67	-8.82	-52.94	-48.39	2	Multi-lobulated mass with well-defined margins									234837							
1175	04/16/2007	939=U Penn	5= >60-70	White	7=Alive	609	7=AC->Tp		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No		2=Grade II (intermediate)	8 = Positive	7 = Positive	0=negative	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		3.5	2=Grade II (intermediate)	0	21	6=Stage IIIB	2=Yes	0=No	0=No	0=No	1=Yes	0=No	1=Yes	1=Yes	6	1	3	1	0	5=Stage IIIA		3=Stable Disease	2=PR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	68	65	60	56	-4.41	-11.76	-17.65	-7.69	-13.85	-6.67	2	Multi-lobulated mass with well-defined margins	235159			240039				240039	235153							
1177	04/16/2007	508=U Ca at San Francisco	3= >40-50	White	7=Alive	574				1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		3=Grade III (high)	0 = Negative	0 = Negative	0=negative	2=FISH				1=Yes, Lumpectomy/Mastectomy or Both				0	14	1=Stage 0 (DCIS only)	2=Yes	1=Yes	1=Yes	0=No	1=Yes	0=No	0=No	0=No	4	3	2	1		4=Stage IIB	2=PR	1=CR	1=CR				Mass	Mass			57	11	0	0	-80.7	-100	-100	-100	-100	0	2	Multi-lobulated mass with well-defined margins									235587							
1179	04/16/2007	372=U North Carolina at Chapel Hill	3= >40-50	White	7=Alive	492	7=AC->Tp		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	1=Yes	0=Negative	2=Grade II (intermediate)	0 = Negative	0 = Negative	0=negative	1=IHC	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both		1.9	3=Grade III (high)		2	2=Stage I	2=Yes	1=Yes	1=Yes	0=No	0=No	0=No	0=No	0=No	6.5						2=PR	2=PR	2=PR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	61	59	55	23	-3.28	-9.84	-62.3	-6.78	-61.02	-58.18	3	Area enhancement with irregular margins (WITH modularity)	236651			241001				241001	236646							
1182	04/16/2007	2051=U Wash	3= >40-50	White	7=Alive	224	7=AC->Tp		1=Yes	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		3=Grade III (high)	0 = Negative	0 = Negative	1=positive(Any 3+ or FISH ratio >= 2)	1=IHC	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both															4.8	3.6	3	1	0	5=Stage IIIA	3=Stable Disease	2=PR	2=PR	2=Anthracycline Plus Taxane			Mass	Mass	Mass	Regonal	48	37	4	21	-22.92	-91.67	-56.25	-89.19	-43.24	425	2	Multi-lobulated mass with well-defined margins									236923							
1184	04/16/2007	2527=U Texas SW Med Ctr	3= >40-50	White	7=Alive	463	7=AC->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No							1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both				0	13	1=Stage 0 (DCIS only)									7	2	3	1	0	5=Stage IIIA	3=Stable Disease	1=CR	1=CR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	40	28	13	5	-30	-67.5	-87.5	-53.57	-82.14	-61.54	2	Multi-lobulated mass with well-defined margins	240982								239263							
1194	04/16/2007	443=Chicago	2= >30-40	White	7=Alive	533	7=AC->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		3=Grade III (high)	8 = Positive	7 = Positive	0=negative	2=FISH	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		1.5	3=Grade III (high)	7	17	5=Stage IIIA															3=Stable Disease	3=Stable Disease	2=PR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Regonal	Regonal	Regonal	Regonal	59	59	55	28	0	-6.78	-52.54	-6.78	-52.54	-49.09	4	Area enhancement with irregular margins (WITHOUT modularity)	238329			244338					238351							
1217	04/16/2007	2647=U Alabama (Birmingham)	4= >50-60	White	7=Alive	256	7=AC->Tp		0=No	5=Indeterminate, not 1 or 2 above	1=Yes	0=Negative	4=Indeterminate			0=negative	1=IHC						0.3			3										5							3=Stable Disease		2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass		25	24	16	0	-4	-36	-100	-33.33	-100	-100	2	Multi-lobulated mass with well-defined margins																
1075	04/16/2007	508=U Ca at San Francisco	2= >30-40	White	7=Alive	1051	6=AC->Td		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		3=Grade III (high)	0 = Negative	0 = Negative	0=negative	1=IHC	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both				0	23	1=Stage 0 (DCIS only)	2=Yes	1=Yes	1=Yes	0=No	1=Yes	0=No	0=No	0=No	6	3	3	1	0	5=Stage IIIA	3=Stable Disease	3=Stable Disease	2=PR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks	0= Standard Therapy, q3 wks	Mass	Mass	Mass		54	27	6	0	-50	-88.89	-100	-77.78	-100	-100	1	Single uni-centric mass with well-defined margin	221380	221391			221380	221391										
1200	04/16/2007	939=U Penn	3= >40-50	White	7=Alive	506	7=AC->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		2=Grade II (intermediate)			0=negative	2=FISH	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both		1.2	2=Grade II (intermediate)	1	14		2=Yes	0=No	0=No	0=No	0=No	0=No	0=No	0=No	4	0.5	2	0	0		3=Stable Disease	2=PR	1=CR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks	0= Standard Therapy, q3 wks	Mass	Mass	Mass	Mass	53	60	62	17	13.21	16.98	-67.92	3.33	-71.67	-72.58	3	Area enhancement with irregular margins (WITH modularity)	238847			245540	238847											
1204	04/16/2007	508=U Ca at San Francisco	2= >30-40	White	7=Alive	547	6=AC->Td		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		3=Grade III (high)	0 = Negative	0 = Negative	0=negative	2=FISH	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both		0.9	3=Grade III (high)	0	3	2=Stage I									3						3=Stable Disease	2=PR	2=PR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks	0= Standard Therapy, q3 wks	Mass	Mass	Mass	Mass	45	32	24		-28.89	-46.67		-25			2	Multi-lobulated mass with well-defined margins																
1187	04/16/2007	372=U North Carolina at Chapel Hill	3= >40-50	Black or African American	7=Alive	506	7=AC->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	1=Yes	0=Negative	3=Grade III (high)	0 = Negative	0 = Negative	0=negative	2=FISH	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		2.5	3=Grade III (high)	0	15	3=Stage IIA		0=No	0=No	0=No	0=No	0=No	0=No	0=No	13		3	0	0	4=Stage IIB	3=Stable Disease	3=Stable Disease	2=PR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	70	59	68	90	-15.71	-2.86	28.57	15.25	52.54	32.35	2	Multi-lobulated mass with well-defined margins	237456															
1063	04/16/2007	530=Mem Sloan-Kettering Cancer Ctr	4= >50-60	White	7=Alive	1096			0=No	5=Indeterminate, not 1 or 2 above	0=No		3=Grade III (high)	5 = Positive	0 = Negative	1=positive(Any 3+ or FISH ratio >= 2)	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both				2	17	3=Stage IIA	2=Yes	0=No	0=No	0=No	1=Yes	0=No	1=Yes	0=No	8		3		0		3=Stable Disease	2=PR	3=Stable Disease		1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Regonal	Regonal	Regonal	Regonal	100	86	60	82	-14	-40	-18	-30.23	-4.65	36.67	5	Septal spread; streaming		219907		244237												
1207	04/16/2007	508=U Ca at San Francisco	2= >30-40	White	7=Alive	516	6=AC->Td		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		3=Grade III (high)	0 = Negative	0 = Negative	0=negative	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both				0	3	1=Stage 0 (DCIS only)									5						3=Stable Disease	1=CR	1=CR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks	0= Standard Therapy, q3 wks	Mass	Mass	Mass		32	22	26	0	-31.25	-18.75	-100	18.18	-100	-100	2	Multi-lobulated mass with well-defined margins																
1154	04/16/2007	2647=U Alabama (Birmingham)	5= >60-70	White	7=Alive	206	7=AC->Tp		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No		2=Grade II (intermediate)			0=negative	2=FISH	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both			2=Grade II (intermediate)	1	12										0		2	0	X	3=Stage IIA	3=Stable Disease	3=Stable Disease		2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	42	34	28	19	-19.05	-33.33	-54.76	-17.65	-44.12	-32.14	1	Single uni-centric mass with well-defined margin	231719			238015	231719			238015								
1183	04/16/2007	372=U North Carolina at Chapel Hill	4= >50-60	White	7=Alive	517	7=AC->Tp		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No			8 = Positive	5 = Positive	0=negative	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		4.5	1=Grade I (low)	5	12	5=Stage IIIA	2=Yes	0=No	1=Yes	0=No	1=Yes	1=Yes	1=Yes	0=No	10		4	0	0		2=PR	2=PR	2=PR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	96	96	60	56	0	-37.5	-41.67	-37.5	-41.67	-6.67	3	Area enhancement with irregular margins (WITH modularity)				242079				242079								
1209	04/16/2007	2647=U Alabama (Birmingham)	3= >40-50	White	7=Alive	197	7=AC->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		2=Grade II (intermediate)	8 = Positive		0=negative	1=IHC	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both		0	2=Grade II (intermediate)	0	7										3.5						3=Stable Disease	2=PR	2=PR	2=Anthracycline Plus Taxane		1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	28	24	24	11	-14.29	-14.29	-60.71	0	-54.17	-54.17	2	Multi-lobulated mass with well-defined margins	240236				240236											
1146	04/16/2007	2647=U Alabama (Birmingham)	4= >50-60	White	9=Lost	223	7=AC->Tp		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No					0=negative	2=FISH	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		0	1=Grade I (low)	2	22	8=Stage IV									3						3=Stable Disease	3=Stable Disease	3=Stable Disease	2=Anthracycline Plus Taxane			Mass	Mass	Mass	Mass	72	59	48	30	-18.06	-33.33	-58.33	-18.64	-49.15	-37.5	3	Area enhancement with irregular margins (WITH modularity)	230875			237608	230875			237608								
1205	04/16/2007	2527=U Texas SW Med Ctr	3= >40-50	Black or African American	9=Lost	191	9=A->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No			7 = Positive	5 = Positive	0=negative	2=FISH																			8	3	3	1	0	5=Stage IIIA	4=Progressive Disease	3=Stable Disease		2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks	0= Standard Therapy, q3 wks	Mass	Mass	Mass	Mass	75	70	47	35	-6.67	-37.33	-53.33	-32.86	-50	-25.53	2	Multi-lobulated mass with well-defined margins	254890				254890											
1232	04/16/2007	939=U Penn	3= >40-50	White	7=Alive	245	16=AC-> TpTd 		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No	1=Positive				0=negative	1=IHC	0=no	1=yes		2= Delayed surgery (>8 weeks); other than primary RT		4.2		0	30	3=Stage IIA		0=No	1=Yes	0=No	1=Yes	0=No	1=Yes	0=No	7	1	3	1	0	5=Stage IIIA	3=Stable Disease		1=CR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks		Regonal	Regonal	Regonal	Regonal	89	26	98	24	-70.79	10.11	-73.03	276.92	-7.69	-75.51	3	Area enhancement with irregular margins (WITH modularity)	244677				244677											
1142	04/16/2007	2647=U Alabama (Birmingham)	1=  18-30	White	7=Alive	176	7=AC->Tp		0=No	5=Indeterminate, not 1 or 2 above	0=No		3=Grade III (high)	0 = Negative	8 = Positive	2=indeterminate(2+)	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both			2=Grade II (intermediate)	10	14	6=Stage IIIB									6	3					3=Stable Disease		2=PR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Regonal	Regonal	Regonal	Regonal	84	79	120	101	-5.95	42.86	20.24	51.9	27.85	-15.83	5	Septal spread; streaming	229951				229951		231311									
1181	04/16/2007	939=U Penn	2= >30-40	White	7=Alive	459	7=AC->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		2=Grade II (intermediate)	7 = Positive	8 = Positive	0=negative	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		1.6	4=Indeterminate	3	5	3=Stage IIA	2=Yes	0=No	0=No	0=No	0=No	0=No	0=No	0=No	8	1	3	1	0	5=Stage IIIA	4=Progressive Disease	1=CR		2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Regonal	Regonal	Regonal	Regonal	114	118	77	76	3.51	-32.46	-33.33	-34.75	-35.59	-1.3	3	Area enhancement with irregular margins (WITH modularity)	236841			241907												
1145	04/16/2007	2647=U Alabama (Birmingham)	2= >30-40	Black or African American	9=Lost	377	7=AC->Tp		0=No		0=No		2=Grade II (intermediate)	0 = Negative	0 = Negative	1=positive(Any 3+ or FISH ratio >= 2)	1=IHC	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both				0	14	4=Indeterminate	2=Yes	1=Yes	1=Yes	0=No	1=Yes	0=No	0=No	0=No	8	4	3	1	X	5=Stage IIIA	3=Stable Disease		1=CR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass			40	17		0	-57.5		-100		-100		2	Multi-lobulated mass with well-defined margins	230572				230572											
1196	04/16/2007	2647=U Alabama (Birmingham)	2= >30-40	White	7=Alive	183	7=AC->Tp		0=No	5=Indeterminate, not 1 or 2 above	1=Yes	1=Positive	3=Grade III (high)	8 = Positive	8 = Positive	1=positive(Any 3+ or FISH ratio >= 2)	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		1	2=Grade II (intermediate)	0	18										2						1=CR			2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Regonal	Regonal	Regonal	Regonal	64	47	37	31	-26.56	-42.19	-51.56	-21.28	-34.04	-16.22	3	Area enhancement with irregular margins (WITH modularity)		238483			238399	238483										
1234	04/16/2007	2647=U Alabama (Birmingham)	2= >30-40	White	7=Alive	201	7=AC->Tp			5=Indeterminate, not 1 or 2 above	0=No		3=Grade III (high)			1=positive(Any 3+ or FISH ratio >= 2)	2=FISH								0	17										5							2=PR	1=CR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass		19	16	12	0	-15.79	-36.84	-100	-25	-100	-100	3	Area enhancement with irregular margins (WITH modularity)																
1212	04/16/2007	2527=U Texas SW Med Ctr	4= >50-60	Black or African American	7=Alive	201	7=AC->Tp		1=Yes	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No		2=Grade II (intermediate)	2 = Negative	0 = Negative	1=positive(Any 3+ or FISH ratio >= 2)	2=FISH	1=yes	0=no		2= Delayed surgery (>8 weeks); other than primary RT				0	16		2=Yes	1=Yes	1=Yes	0=No	1=Yes	0=No	0=No	0=No	7	2	3	1	0	5=Stage IIIA	3=Stable Disease	2=PR	1=CR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks		Mass	Mass	Mass		87	85	60	1	-2.3	-31.03	-98.85	-29.41	-98.82	-98.33	2	Multi-lobulated mass with well-defined margins					248290											
1170	04/16/2007	530=Mem Sloan-Kettering Cancer Ctr	3= >40-50	White	7=Alive	608	7=AC->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		2=Grade II (intermediate)	8 = Positive	8 = Positive	0=negative	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		4.7	2=Grade II (intermediate)	7	12	5=Stage IIIA	2=Yes	0=No	0=No	1=Yes	1=Yes	1=Yes	1=Yes	0=No	5		3	1	0	5=Stage IIIA		2=PR	2=PR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks		Mass	Mass	Mass	50	60	22	75	20	-56	50	-63.33	25	240.91	4	Area enhancement with irregular margins (WITHOUT modularity)				244232				244232								
1213	04/16/2007	2051=U Wash	2= >30-40	Asian	7=Alive	192	5=A		1=Yes									0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both						3=Stage IIA									3.7		2	0	0	3=Stage IIA	3=Stable Disease	3=Stable Disease		1=Anthracycline Only Regimen			Mass	Mass	Mass		37	34	31	0	-8.11	-16.22	-100	-8.82	-100	-100	4	Area enhancement with irregular margins (WITHOUT modularity)	240414															
1159	04/16/2007	939=U Penn	4= >50-60	Black or African American	8=Dead	574	22=AC->Td->Navelbine->Xeloda		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No							0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		4	3=Grade III (high)	1	12	4=Indeterminate	2=Yes	0=No	0=No	1=Yes	1=Yes	0=No	1=Yes	1=Yes	7	0.5	3	1	0	5=Stage IIIA	3=Stable Disease	3=Stable Disease	2=PR	4=Anthracycline + Taxane + Other	0= Standard Therapy, q3 wks		Mass	Mass	Mass	Mass	65	54	54	54	-16.92	-16.92	-16.92	0	0	0	2	Multi-lobulated mass with well-defined margins				238509				238509								
1238	04/16/2007	939=U Penn	4= >50-60	Black or African American	7=Alive	255	6=AC->Td																						0=No	0=No	0=No	0=No	0=No	0=No	0=No	6	2								2=Anthracycline Plus Taxane		0= Standard Therapy, q3 wks	Mass				48										2	Multi-lobulated mass with well-defined margins																
1198	04/16/2007	2647=U Alabama (Birmingham)	4= >50-60	Black or African American	7=Alive	407	24=C->Tp		0=No	5=Indeterminate, not 1 or 2 above	0=No	0=Negative	4=Indeterminate			0=negative	1=IHC	1=yes	1=yes		1=Yes, Lumpectomy/Mastectomy or Both				0	20	4=Indeterminate		0=No	1=Yes	0=No	1=Yes	1=Yes	1=Yes	1=Yes	5						2=PR	2=PR	1=CR		1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks		Regonal	Regonal	Regonal	44	45	45	37	2.27	2.27	-15.91	0	-17.78	-17.78	3	Area enhancement with irregular margins (WITH modularity)				246252	239010											
1225	04/16/2007	939=U Penn	3= >40-50	White	7=Alive	346	7=AC->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	1=Yes	1=Positive				0=negative	2=FISH						1.1		8	19			1=Yes	0=No	0=No	1=Yes	0=No	0=No	1=Yes	1.5	1					2=PR	2=PR		2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	89	86	22	12	-3.37	-75.28	-86.52	-74.42	-86.05	-45.45	3	Area enhancement with irregular margins (WITH modularity)	243157			248526												
1174	04/16/2007	2647=U Alabama (Birmingham)	3= >40-50	White	8=Dead	509	7=AC->Tp		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No		2=Grade II (intermediate)	8 = Positive	8 = Positive	0=negative	2=FISH	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		0	3=Grade III (high)	5	6	5=Stage IIIA	2=Yes	0=No	1=Yes	0=No	1=Yes	0=No	1=Yes	0=No	6	3	3	1	X	5=Stage IIIA	3=Stable Disease		2=PR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	83	83	75	75	0	-9.64	-9.64	-9.64	-9.64	0	3	Area enhancement with irregular margins (WITH modularity)																
1219	04/16/2007	939=U Penn	3= >40-50	White	7=Alive	390	1=AC			1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	1=Yes	0=Negative	2=Grade II (intermediate)					1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both		3	2=Grade II (intermediate)			3=Stage IIA	2=Yes	0=No	0=No	0=No	0=No	0=No	0=No	0=No	5.5						3=Stable Disease		3=Stable Disease	1=Anthracycline Only Regimen	1= Dose Dense Therapy, q2 wks		Mass	Mass	Mass		53	49	40		-7.55	-24.53		-18.37			4	Area enhancement with irregular margins (WITHOUT modularity)	243504			247073	243504											
1197	04/16/2007	2647=U Alabama (Birmingham)	3= >40-50	White	7=Alive	294	7=AC->Tp		0=No	5=Indeterminate, not 1 or 2 above	1=Yes	1=Positive	4=Indeterminate		3 = Positive			0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		0	3=Grade III (high)	0	16	4=Indeterminate	2=Yes	0=No	1=Yes	0=No	1=Yes	1=Yes	1=Yes	0=No	5	1					2=PR		4=Progressive Disease	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	158	145	123	126	-8.23	-22.15	-20.25	-15.17	-13.1	2.44	5	Septal spread; streaming	238587			243228	238587											
1195	04/16/2007	372=U North Carolina at Chapel Hill	2= >30-40	Unknown	9=Lost	6				1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		3=Grade III (high)	7 = Positive	1 = Negative	0=negative	1=IHC				6=No, Other Reason, Not specified															7	4	3	1	X	5=Stage IIIA																																						
1215	04/16/2007	2527=U Texas SW Med Ctr	3= >40-50	White	7=Alive	421	7=AC->Tp		1=Yes	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		2=Grade II (intermediate)	7 = Positive	6 = Positive	1=positive(Any 3+ or FISH ratio >= 2)	2=FISH	0=no	1=yes		2= Delayed surgery (>8 weeks); other than primary RT				0	6			0=No	1=Yes	0=No	1=Yes	0=No	1=Yes	0=No		1	4	3		6=Stage IIIB		2=PR	1=CR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks																		254900				254900											
1216	04/16/2007	508=U Ca at San Francisco	2= >30-40	White	7=Alive	414	7=AC->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		2=Grade II (intermediate)	0 = Negative	0 = Negative	0=negative	1=IHC	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both				0	29	1=Stage 0 (DCIS only)	2=Yes	1=Yes	1=Yes	0=No	1=Yes	0=No	0=No	0=No	2.5	7					3=Stable Disease	1=CR	1=CR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass			55	45	44	0	-18.18	-20	-100	-2.22	-100	-100	2	Multi-lobulated mass with well-defined margins	254433				254433											
1218	04/16/2007	372=U North Carolina at Chapel Hill	3= >40-50	Black or African American	7=Alive	295	7=AC->Tp		0=No	5=Indeterminate, not 1 or 2 above	1=Yes	1=Positive	3=Grade III (high)			0=negative	1=IHC	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both		0.1		0	28	2=Stage I									6	2	3	1	0	5=Stage IIIA	2=PR	1=CR	1=CR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass		113	94	44	0	-16.81	-61.06	-100	-53.19	-100	-100	3	Area enhancement with irregular margins (WITH modularity)	244359				244359											
1210	04/16/2007	939=U Penn	3= >40-50	White	7=Alive	490	7=AC->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		2=Grade II (intermediate)	8 = Positive	8 = Positive			0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		1.1		2	15	3=Stage IIA	2=Yes	0=No	0=No	0=No	1=Yes	0=No	1=Yes	0=No	8		3	0	0	4=Stage IIB	2=PR	2=PR	1=CR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	83	66	37	10	-20.48	-55.42	-87.95	-43.94	-84.85	-72.97	3	Area enhancement with irregular margins (WITH modularity)																
1223	04/16/2007	508=U Ca at San Francisco	4= >50-60	White	7=Alive	361	7=AC->Tp		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)			2=Grade II (intermediate)	8 = Positive	8 = Positive	0=negative	1=IHC	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both		3	2=Grade II (intermediate)	0	3	3=Stage IIA		1=Yes	1=Yes	0=No	1=Yes	0=No	0=No	0=No	4						3=Stable Disease	3=Stable Disease	3=Stable Disease	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	27		15	14		-44.44	-48.15			-6.67	2	Multi-lobulated mass with well-defined margins	254439				254439											
1237	04/16/2007	372=U North Carolina at Chapel Hill	3= >40-50	White	7=Alive	356				1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		3=Grade III (high)	8 = Positive	8 = Positive	1=positive(Any 3+ or FISH ratio >= 2)	1=IHC						0.5		3	28			0=No	1=Yes	1=Yes	1=Yes	1=Yes	1=Yes	0=No	2	2	4	1	X	6=Stage IIIB	3=Stable Disease	3=Stable Disease	1=CR				Mass	Mass	Mass	Mass	60	60	37	36	0	-38.33	-40	-38.33	-40	-2.7	1	Single uni-centric mass with well-defined margin	245509			252823	245509											
1235	04/16/2007	372=U North Carolina at Chapel Hill	5= >60-70	White	7=Alive	85				2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No		3=Grade III (high)	0 = Negative	0 = Negative	1=positive(Any 3+ or FISH ratio >= 2)	1=IHC																			6	1.2	3	1	0	5=Stage IIIA	2=PR	2=PR					Mass	Mass	Mass		52	50	28	0	-3.85	-46.15	-100	-44	-100	-100	3	Area enhancement with irregular margins (WITH modularity)																
1236	04/16/2007	372=U North Carolina at Chapel Hill	2= >30-40	Black or African American	7=Alive	383				1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		3=Grade III (high)	0 = Negative	4 = Positive	0=negative	1=IHC	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both		1.3	3=Grade III (high)	2	15	3=Stage IIA		1=Yes	1=Yes	0=No	1=Yes	0=No	0=No	0=No	3.5	1.5	2	1	X	4=Stage IIB	2=PR	2=PR	2=PR				Mass	Mass	Mass	Mass	51	52	35	23	1.96	-31.37	-54.9	-32.69	-55.77	-34.29	3	Area enhancement with irregular margins (WITH modularity)	245829				245829											
1192	04/16/2007	2647=U Alabama (Birmingham)	2= >30-40	Black or African American	7=Alive	431	7=AC->Tp		0=No	5=Indeterminate, not 1 or 2 above	0=No		4=Indeterminate			2=indeterminate(2+)	1=IHC	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both				0	16	1=Stage 0 (DCIS only)	2=Yes	0=No	1=Yes	0=No	1=Yes	0=No	0=No	0=No	2	3					2=PR	1=CR	1=CR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass				25	78	0	0	212	-100	-100	-100	-100	0	2	Multi-lobulated mass with well-defined margins	237773			244729												
1221	04/16/2007	939=U Penn	4= >50-60	White	7=Alive	327	7=AC->Tp		1=Yes	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)			2=Grade II (intermediate)			1=positive(Any 3+ or FISH ratio >= 2)	1=IHC						13		3	10										25		4		0		3=Stable Disease	3=Stable Disease	3=Stable Disease	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks		Regonal	Regonal	Regonal	Regonal	117	100	114	114	-14.53	-2.56	-2.56	14	14	0	4	Area enhancement with irregular margins (WITHOUT modularity)	242696			248391	242696											
1208	04/16/2007	939=U Penn	3= >40-50	White	7=Alive	523	7=AC->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		3=Grade III (high)	0 = Negative	0 = Negative	0=negative	2=FISH	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both				0	20	1=Stage 0 (DCIS only)	2=Yes	0=No	0=No	0=No	0=No	0=No	1=Yes	0=No	12		3	0	0	4=Stage IIB	3=Stable Disease	2=PR	2=PR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Regonal	Regonal			166	119		0	-28.31		-100		-100		5	Septal spread; streaming	239734				239734											
1230	04/16/2007	372=U North Carolina at Chapel Hill	4= >50-60	Black or African American	8=Dead	190				2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	1=Yes	1=Positive	3=Grade III (high)	0 = Negative	3 = Positive	0=negative	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		14	3=Grade III (high)	26	28	7=Stage IIIC									5.5	5	3	3	0		3=Stable Disease	4=Progressive Disease	4=Progressive Disease				Mass	Mass	Mass	Mass	60	61	72	60	1.67	20	0	18.03	-1.64	-16.67	3	Area enhancement with irregular margins (WITH modularity)				252038												
1231	04/16/2007	508=U Ca at San Francisco	3= >40-50	White	7=Alive	357	7=AC->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		1=Grade I (low)	6 = Positive	7 = Positive	0=negative	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		8.5	2=Grade II (intermediate)	3	6	5=Stage IIIA									7						3=Stable Disease	3=Stable Disease	3=Stable Disease	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Regonal		Regonal	Regonal	81		64	56		-20.99	-30.86			-12.5	3	Area enhancement with irregular margins (WITH modularity)	254447			254587												
1185	04/16/2007	508=U Ca at San Francisco	3= >40-50	White	7=Alive	608				1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		4=Indeterminate			0=negative	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		10	2=Grade II (intermediate)	6	28	5=Stage IIIA	2=Yes	0=No	0=No	1=Yes	1=Yes	0=No	1=Yes	1=Yes	6		3	0	0	4=Stage IIB	3=Stable Disease		2=PR				Regonal	Regonal	Regonal		71	51	19	0	-28.17	-73.24	-100	-62.75	-100	-100	5	Septal spread; streaming				254544				254544								
1118	04/16/2007	2647=U Alabama (Birmingham)	2= >30-40	White	7=Alive	187	7=AC->Tp		0=No	5=Indeterminate, not 1 or 2 above	1=Yes	0=Negative	2=Grade II (intermediate)	8 = Positive	8 = Positive			1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both					2	1=Stage 0 (DCIS only)									8		3	0	X	4=Stage IIB	3=Stable Disease	1=CR	1=CR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks		Regonal	Regonal	Regonal		36	45	50	0	25	38.89	-100	11.11	-100	-100	4	Area enhancement with irregular margins (WITHOUT modularity)	226342				226342											
1224	04/16/2007	372=U North Carolina at Chapel Hill	5= >60-70	Black or African American	7=Alive	190	7=AC->Tp		0=No	5=Indeterminate, not 1 or 2 above	0=No		3=Grade III (high)	8 = Positive	2 = Negative	1=positive(Any 3+ or FISH ratio >= 2)	1=IHC	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both				0	19	2=Stage I									4	2	2	1		4=Stage IIB	3=Stable Disease	2=PR	1=CR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks		Mass	Mass	Mass		24	26	19	0	8.33	-20.83	-100	-26.92	-100	-100	1	Single uni-centric mass with well-defined margin																
1211	04/16/2007	443=Chicago	3= >40-50	White	7=Alive	336	7=AC->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No					0=negative	2=FISH	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both			1=Grade I (low)	2	2										6.5						3=Stable Disease		2=PR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Regonal		57	54	45	0	-5.26	-21.05	-100	-16.67	-100	-100	3	Area enhancement with irregular margins (WITH modularity)	242624				242624											
1202	04/16/2007	372=U North Carolina at Chapel Hill	4= >50-60	White	7=Alive	456	7=AC->Tp		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	1=Yes	1=Positive	3=Grade III (high)	8 = Positive	0 = Negative	0=negative	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both				0	0		2=Yes	0=No	0=No	0=No	0=No	0=No	0=No	0=No	5		2	1	0	4=Stage IIB	3=Stable Disease	2=PR	2=PR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass		80	75	35	0	-6.25	-56.25	-100	-53.33	-100	-100	3	Area enhancement with irregular margins (WITH modularity)	239357				239357											
1220	04/16/2007	508=U Ca at San Francisco	3= >40-50	White	7=Alive	334	6=AC->Td		0=No	5=Indeterminate, not 1 or 2 above	0=No							0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both				0	12	1=Stage 0 (DCIS only)		0=No	0=No	0=No	1=Yes	0=No	1=Yes	0=No	2.8	2					3=Stable Disease	2=PR	2=PR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks	0= Standard Therapy, q3 wks	Mass	Mass	Mass		79	72	17	0	-8.86	-78.48	-100	-76.39	-100	-100	2	Multi-lobulated mass with well-defined margins	254435				254435											
1228	04/16/2007	2051=U Wash	4= >50-60	Black or African American	7=Alive	107																																										Regonal	Regonal	Regonal	Regonal	120	117	6	5	-2.5	-95	-95.83	-94.87	-95.73	-16.67	3	Area enhancement with irregular margins (WITH modularity)	244617															
1227	04/16/2007	508=U Ca at San Francisco	3= >40-50	White	7=Alive	370	7=AC->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		3=Grade III (high)	0 = Negative	0 = Negative	0=negative	1=IHC	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both				0	6	1=Stage 0 (DCIS only)		0=No	0=No	0=No	1=Yes	0=No	0=No	0=No	5.5						3=Stable Disease	2=PR	1=CR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass			49	57		0	16.33		-100		-100		1	Single uni-centric mass with well-defined margin	254443				254443											
1188	04/16/2007	2647=U Alabama (Birmingham)	2= >30-40	Black or African American	7=Alive	199	7=AC->Tp		0=No	5=Indeterminate, not 1 or 2 above	0=No		3=Grade III (high)	0 = Negative	0 = Negative	0=negative	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both			3=Grade III (high)	2	18										4	3					3=Stable Disease			2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	20	18	12	10	-10	-40	-50	-33.33	-44.44	-16.67	2	Multi-lobulated mass with well-defined margins	237515			244724				244724								
1173	04/16/2007	530=Mem Sloan-Kettering Cancer Ctr	3= >40-50	Black or African American	7=Alive	482	7=AC->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	1=Yes		3=Grade III (high)					0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both				1	31	5=Stage IIIA									3	4.5	2	2		5=Stage IIIA	2=PR	1=CR	2=PR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass				21		0	0		-100	-100			0	2	Multi-lobulated mass with well-defined margins	238045			244231				244231								
1125	04/16/2007	2527=U Texas SW Med Ctr	3= >40-50	American Indian or Alaska Native	7=Alive	841	7=AC->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	1=Yes	1=Positive		7 = Positive	8 = Positive	0=negative	1=IHC	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both		4.8	2=Grade II (intermediate)	0	12	4=Indeterminate	2=Yes	1=Yes	1=Yes	0=No	1=Yes	0=No	0=No	0=No	4.5		2	0	0	3=Stage IIA	3=Stable Disease	3=Stable Disease	2=PR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Regonal	Regonal	Regonal	Regonal	85	78	80	55	-8.24	-5.88	-35.29	2.56	-29.49	-31.25	3	Area enhancement with irregular margins (WITH modularity)	228350	228361														
1226	04/16/2007	508=U Ca at San Francisco	3= >40-50	White	7=Alive	338	7=AC->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		3=Grade III (high)	8 = Positive	8 = Positive	0=negative	1=IHC	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both		1.1	2=Grade II (intermediate)	1	13	2=Stage I									3	1.5					3=Stable Disease	2=PR	2=PR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	49	43	41	28	-12.24	-16.33	-42.86	-4.65	-34.88	-31.71	1	Single uni-centric mass with well-defined margin	254441			254578												
1229	04/16/2007	508=U Ca at San Francisco	4= >50-60	White	7=Alive	357	24=C->Tp																		0	9			1=Yes	0=No	0=No	1=Yes	0=No	1=Yes	0=No	6.5	2					3=Stable Disease	2=PR	2=PR			1= Dose Dense Therapy, q2 wks	Mass	Mass		Mass	56	43	21	4	-23.21	-62.5	-92.86	-51.16	-90.7	-80.95	2	Multi-lobulated mass with well-defined margins																
1189	04/16/2007	508=U Ca at San Francisco	5= >60-70	Asian	7=Alive	581	7=AC->Tp			2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No		3=Grade III (high)	0 = Negative	0 = Negative	1=positive(Any 3+ or FISH ratio >= 2)	1=IHC											2=Yes	1=Yes	0=No	0=No	0=No	0=No	0=No	0=No	5		3	0	0	4=Stage IIB	2=PR	1=CR	1=CR	2=Anthracycline Plus Taxane			Mass	Mass			33	26	0	0	-21.21	-100	-100	-100	-100	0	2	Multi-lobulated mass with well-defined margins																
1214	04/16/2007	508=U Ca at San Francisco	3= >40-50	Black or African American	7=Alive	412	7=AC->Tp		1=Yes	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		2=Grade II (intermediate)	7 = Positive	4 = Positive	0=negative	2=FISH	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both				0	3										6							2=PR	2=PR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks		Mass		Mass	Mass	84		42	38		-50	-54.76			-9.52	3	Area enhancement with irregular margins (WITH modularity)				255580												
1161	04/16/2007	2647=U Alabama (Birmingham)	4= >50-60	White	7=Alive	174	7=AC->Tp		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No		3=Grade III (high)	0 = Negative	0 = Negative	1=positive(Any 3+ or FISH ratio >= 2)	2=FISH	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		0		3	11	8=Stage IV									8	4	3	1	X	5=Stage IIIA	2=PR	1=CR	1=CR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass		81	63	18	0	-22.22	-77.78	-100	-71.43	-100	-100	1	Single uni-centric mass with well-defined margin	232542				232542											
1233	04/16/2007	372=U North Carolina at Chapel Hill	1=  18-30	Black or African American	7=Alive	286	7=AC->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	1=Yes	0=Negative	2=Grade II (intermediate)	8 = Positive	0 = Negative	0=negative	1=IHC	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both		0.6	1=Grade I (low)		1	2=Stage I		1=Yes	1=Yes	0=No	0=No	0=No	0=No	0=No	4.5		2	0	0	3=Stage IIA	3=Stable Disease	3=Stable Disease	2=PR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	26	18	11	3	-30.77	-57.69	-88.46	-38.89	-83.33	-72.73	2	Multi-lobulated mass with well-defined margins																
1172	04/16/2007	2647=U Alabama (Birmingham)	3= >40-50	White	7=Alive	334	7=AC->Tp		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	1=Yes	0=Negative	2=Grade II (intermediate)	0 = Negative	0 = Negative	0=negative	2=FISH	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both			3=Grade III (high)				2=Yes	0=No	1=Yes	0=No	0=No	0=No	0=No	0=No	5.4		2	0	X	3=Stage IIA	3=Stable Disease		2=PR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	41	40	22	10	-2.44	-46.34	-75.61	-45	-75	-54.55	2	Multi-lobulated mass with well-defined margins	234941															
1193	04/16/2007	939=U Penn	4= >50-60	White	7=Alive	323	16=AC-> TpTd 		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)			1=Grade I (low)			0=negative	1=IHC	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both		2.7	1=Grade I (low)	3	17	4=Indeterminate	2=Yes	0=No	0=No	0=No	0=No	0=No	0=No	0=No	3.5						2=PR	2=PR		2=Anthracycline Plus Taxane			Mass	Mass	Mass	Mass	37	38	28	29	2.7	-24.32	-21.62	-26.32	-23.68	3.57	1	Single uni-centric mass with well-defined margin	237951			243530	237951											
1239	04/16/2007	508=U Ca at San Francisco	3= >40-50	Asian	7=Alive	188	6=AC->Td		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		2=Grade II (intermediate)			0=negative	1=IHC	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both		6	2=Grade II (intermediate)	0	6	4=Indeterminate									4						3=Stable Disease	2=PR		2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks	0= Standard Therapy, q3 wks	Regonal	Regonal	Regonal	Regonal	74	63	12	10	-14.86	-83.78	-86.49	-80.95	-84.13	-16.67	3	Area enhancement with irregular margins (WITH modularity)	254449				254449											
1199	04/16/2007	939=U Penn	2= >30-40	White	8=Dead	476	7=AC->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)			3=Grade III (high)			0=negative	4=Unknown	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		7	3=Grade III (high)	6	37	4=Indeterminate									8	1					3=Stable Disease	3=Stable Disease	4=Progressive Disease	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	78	70	65	65	-10.26	-16.67	-16.67	-7.14	-7.14	0	2	Multi-lobulated mass with well-defined margins	238715			243785	238715											
1201	04/16/2007	372=U North Carolina at Chapel Hill	4= >50-60	White	7=Alive	464	7=AC->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	1=Yes	0=Negative	2=Grade II (intermediate)	8 = Positive	8 = Positive	0=negative	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both			2=Grade II (intermediate)		2	4=Indeterminate									6		3	0	0	4=Stage IIB	3=Stable Disease	3=Stable Disease	2=PR	2=Anthracycline Plus Taxane		1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	78	73	53	60	-6.41	-32.05	-23.08	-27.4	-17.81	13.21	3	Area enhancement with irregular margins (WITH modularity)																
1206	04/16/2007	530=Mem Sloan-Kettering Cancer Ctr	3= >40-50	White	8=Dead	481	7=AC->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	0=No		3=Grade III (high)	8 = Positive	5 = Positive	0=negative	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		2.4		5	8	5=Stage IIIA	2=Yes	0=No	0=No	0=No	1=Yes	0=No	1=Yes	0=No	6	1.5	3	2	0	5=Stage IIIA	3=Stable Disease	2=PR	1=CR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	78	78	35	26	0	-55.13	-66.67	-55.13	-66.67	-25.71	2	Multi-lobulated mass with well-defined margins	244242			244241	244242											
1163	04/16/2007	2647=U Alabama (Birmingham)	2= >30-40	White	7=Alive	183	7=AC->Tp		0=No	5=Indeterminate, not 1 or 2 above	0=No		3=Grade III (high)	0 = Negative	0 = Negative	0=negative	2=FISH	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both		0			8												2	0	X	3=Stage IIA	3=Stable Disease		1=CR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass		33	41	11	0	24.24	-66.67	-100	-73.17	-100	-100	2	Multi-lobulated mass with well-defined margins	233168															
1166	04/16/2007	2647=U Alabama (Birmingham)	4= >50-60	White	7=Alive	577	7=AC->Tp		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No		2=Grade II (intermediate)	8 = Positive	8 = Positive	0=negative	2=FISH	1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both				0	18		2=Yes	1=Yes	1=Yes	0=No	1=Yes	0=No	0=No	0=No	5	3	1	0	X		2=PR		1=CR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass			58	62	0	0	6.9	-100	-100	-100	-100	0	3	Area enhancement with irregular margins (WITH modularity)	233357				233357											
1176	04/16/2007	2647=U Alabama (Birmingham)	3= >40-50	White	7=Alive	234	7=AC->Tp		1=Yes	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	1=Yes	0=Negative	3=Grade III (high)	0 = Negative	0 = Negative	1=positive(Any 3+ or FISH ratio >= 2)	2=FISH	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both				0	15										6		3	0	X	4=Stage IIB	3=Stable Disease		1=CR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	0= Standard Therapy, q3 wks	Mass	Mass			43	38			-11.63						3	Area enhancement with irregular margins (WITH modularity)	235532															
1180	04/16/2007	530=Mem Sloan-Kettering Cancer Ctr	2= >30-40	White	7=Alive	469	7=AC->Tp		0=No		0=No		3=Grade III (high)	8 = Positive	5 = Positive	0=negative	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		0.5	3=Grade III (high)	1	18	6=Stage IIIB	2=Yes	0=No	0=No	0=No	1=Yes	0=No	1=Yes	0=No	5	1.5	4	1	0	6=Stage IIIB	3=Stable Disease	1=CR	1=CR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	47	16	40	4	-65.96	-14.89	-91.49	150	-75	-90	2	Multi-lobulated mass with well-defined margins	244256															
1030	04/16/2007	508=U Ca at San Francisco	4= >50-60	Asian	7=Alive	1104	6=AC->Td		0=No		0=No		4=Indeterminate					1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both				0	21	1=Stage 0 (DCIS only)	2=Yes	1=Yes	1=Yes	0=No	1=Yes	0=No	0=No	1=Yes	2.5	5					3=Stable Disease	2=PR	1=CR	2=Anthracycline Plus Taxane	0= Standard Therapy, q3 wks	0= Standard Therapy, q3 wks	Regonal	Regonal	Regonal	Regonal	49	47	42	41	-4.08	-14.29	-16.33	-10.64	-12.77	-2.38	3	Area enhancement with irregular margins (WITH modularity)																
1222	04/16/2007	508=U Ca at San Francisco	4= >50-60	White	7=Alive	382												1=yes	0=no		1=Yes, Lumpectomy/Mastectomy or Both		1.5	2=Grade II (intermediate)	0	8	2=Stage I		1=Yes	0=No	0=No	1=Yes	0=No	0=No	0=No													Mass	Mass	Mass		56	61	67	0	8.93	19.64	-100	9.84	-100	-100	2	Multi-lobulated mass with well-defined margins	254437			254568												
1144	04/16/2007	2647=U Alabama (Birmingham)	4= >50-60	White	7=Alive	541	7=AC->Tp		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No		3=Grade III (high)					0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		0		0	5		2=Yes	0=No	1=Yes	0=No	1=Yes	1=Yes	1=Yes	0=No	5	1					3=Stable Disease		1=CR	2=Anthracycline Plus Taxane		1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	47	46	26	18	-2.13	-44.68	-61.7	-43.48	-60.87	-30.77	1	Single uni-centric mass with well-defined margin	230370				230370		231801									
1191	04/16/2007	2647=U Alabama (Birmingham)	3= >40-50	White	7=Alive	379	7=AC->Tp		0=No	2= Post (prior bilateral ovariectomy OR > 12 mo since LMP with no prior hysterectomy)	0=No		2=Grade II (intermediate)			0=negative	1=IHC	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both				0	17		2=Yes	0=No	0=No	0=No	0=No	0=No	0=No	0=No	5	2					3=Stable Disease	2=PR	1=CR	2=Anthracycline Plus Taxane		1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	37	36	26	9	-2.7	-29.73	-75.68	-27.78	-75	-65.38	1	Single uni-centric mass with well-defined margin	238117			244719				244719								
1203	04/16/2007	939=U Penn	3= >40-50	White	7=Alive	526	7=AC->Tp		0=No	1=Pre (<6 mo since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement)	1=Yes	1=Positive	1=Grade I (low)			0=negative	3=Other	0=no	1=yes		1=Yes, Lumpectomy/Mastectomy or Both		1.3	2=Grade II (intermediate)	0	2	3=Stage IIA	2=Yes	1=Yes	1=Yes	1=Yes	0=No	0=No	1=Yes	0=No	7		3	2	0	5=Stage IIIA	3=Stable Disease	3=Stable Disease	2=PR	2=Anthracycline Plus Taxane	1= Dose Dense Therapy, q2 wks	1= Dose Dense Therapy, q2 wks	Mass	Mass	Mass	Mass	105	99	6	87	-5.71	-94.29	-17.14	-93.94	-12.12	1350	3	Area enhancement with irregular margins (WITH modularity)	239105			244535	239105											
